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Abstract
Breast cancer is a malignant tumor, commonly found in women but rarely in men. One in
eight US women will have the chance of developing breast cancer in their lifetime. A family
history analysis and genetic test can identify the potential carrier gene that cause hereditary
breast cancer. Mutated genes such as BRCA1, BRCA2, Tp53 and PTEN confer high lifetime risk
of breast cancers and are the most significant genes for clinical studies. The study goals of this
thesis were to: 1) develop an open source software tool to predict the risk of hereditary breast
cancer and mutation risk of breast cancer in any person, 2) predict the risk of hereditary breast
cancer in the next generation by analyzing the inheritance patterns of the genes, and 3) exploit
medical guidelines and connect it with information technology.
In the program, we combine National Comprehensive Cancer Network (NCCN)
guidelines of BRCA1/BRCA2, TP53, and PTEN gene mutations. We have sought the help of
medical practitioners, medical literatures, and all other credential reports to validate the output of
this research. The input data for this program are family history and other cancer risk assessment
guidelines for the individual. We have developed this software tool in C++ and JavaScript. In the
program, we identify a person’s family history, age, and gender through questionnaires and make
an evaluation of different possibilities and outcome. We analyze the risk of mutation with the
help of family history. We have considered first, second, and third-degree relatives and
individuals who belong to Ashkenazi Jewish ancestry.
After the analysis, and if the person is at risk, we predict the mutation risk of the next
generation based on the gene’s inheritance pattern. This tool would help the members of the
general public who have the least knowledge about breast cancer and genetic inheritance, and it
would also help them to identify the presence of mutated genes.
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CHAPTER 1
Introduction

Medical data that is stored in computers present many promising advantages in medical
research. Nowadays, medical reports and health information are becoming more available as the
generations pass. Therefore, research that exploits medical data brings new advancements in
medical systems. In this computer-driven world, genome mapping and medical technology have
made it possible to get genetic information at low cost, which was not possible earlier. Advances
in computer processing and medical technology made it possible to get a genome mapping of
any person quickly. We can exploit these advancements to assess a person’s risk factors for any
given diseases that are inherited or related to a genetic defect. The Human Genome Project
(HGP) is an international scientific research project with a primary goal of determining the
sequence of chemical base pairs, which make up human DNA (Williams, 1997). It took efforts of
several international institutes to complete, and remains the world’s largest collaborative
biological project. The HGP has identified about 20,500 human genes and provides information
about the structure and whole functions of human genes. As the years go by, family health
history stored in computers provides better assessments, accuracy, and standardization in
forecasting diseases. Combining all known diseases, symptoms, and diagnoses helps medical
practitioners to determine and forecast diseases in the current or next generations. Computers
could be trained to forecast and predict specific diseases.
A family history gives a report about a person and his or her relatives (Agrawal,
Suleiman, Seay, & Gloster, 2013). Families have many common factors, such as genes, lifestyle,
environment and ethnic background. These common factors can be related to some medical
conditions that run in a family. We can use genetic reports, family medical history, medical
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reports, and lab reports to forecast a person’s probability of getting diseases that are inherited.
Getting genome mapping helps to diagnose some hereditary diseases. Even though, we cannot
change the existing gene pattern, we can be informed and take precautions based on the available
reports. Integrating medical, family, and genetic reports will help to predict hereditary diseases
such as cancer, diabetics, and asthma. Furthermore, study and research about cancer is on the rise
for various reasons. The World Health Organization estimates significant growth in cancer
patients worldwide, and cancer is poised to overtake heart disease as the world’s top killer. There
are about two hundred cancers known at this time. The primary factor in cancer is the
uncontrollable growth of cells. Cancer screening can be used to detect early symptoms of cancer.
There are different reasons for cancer, and the primary reason is environmental factors, which
include tobacco use, diet, obesity, infections, radiations, stress, lack of physical activity, and
pollutants. Everyone has the risk of developing cancer in his or her lifetime. The factors behind
developing cancer include age, lifestyle, chemicals, radiation, genetics, immune system, and
infection. Most of the cancers are non-hereditary, and inherited genetic defect commonly causes
hereditary cancers. Hereditary cancer is associated with highly penetrant genes, and pass to the
next generation through different inheritance patterns. Hereditary cancer can be predicted earlier
based on a pedigree analysis. A pedigree is a chart or diagram of family history analysis that
includes parents, grandparents, and previous generations, and it checks the occurrence of any
inherited diseases. The information collected from pedigree analysis is useful to determine the
cancer risk for an individual or his/her progeny.
Cancer can be predicted in current or future generations based on the information
gathered from family history tools, genetic and medical guidelines. Family health history plays
an important role in determining the risk factors as it gives a link to hereditary, environmental,
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cultural, and behavioral factors of the entire family (Aiello-Laws, 2011). The risk can be
considered high, moderate, and average, based on the number of the family affected and age at
the onset of the people who are affected in the family (Yoon et al., 2002). In this thesis, we have
focused on predicting the risk of mutated genes that cause breast cancer, as most of the
hereditary cancers are predictable at early stages.
Breast cancer can occur in both men and women, but it is far more common for women.
A family history analysis and genetic test can identify the potential carrier gene behind breast
cancer. Breast cancer is a malignant tumor which is capable of spreading into surrounding tissues
or to distant areas. The risk factors involved with breast cancers are age, gender, genetic factors,
family history, race/ethnicity, and habits. Breast cancer occurs in more often in females than in
males because of the female hormones like estrogen and progesterone, which help cancer cell
growth. The risk of developing breast cancer increases with age. Mutated genes such as BRCA1,
BRCA2, PTEN, and Tp53 make the individual at high lifetime risk of breast cancer (Cancer
Research UK, 2014). There are other genes such as PALB1, BRIP and LKB1 behind breast
cancer, which contribute moderate risk. However, BRCA1, BRCA2, TP53, and PTEN are the
genes considered most for clinical studies (Allain, 2008). The rest of the paper is organized as
follows: Section 1.2 discusses the problem statement, and motivation for this thesis and Chapter
2 presents literature review. Chapter 3 explains different breast cancer prediction models
available to predict cancer. Chapter 4 provides details about the analysis of hereditary
information in predicting breast cancer. Chapter 5 explains the prediction of hereditary breast
cancer risk in current and next generations, and Chapter 6 discusses future work.
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1.1 What is Cancer?
Cancer is a general term used to define abnormal cell division, and it attacks other
tissues. Cancer spreads into the body through the blood and lymphatic systems. The cell is the
basic unit of our bodies. All living things are made up of cells. The human body is made up of
different kinds of cells. Different cells have different functions in the body (Williams, 1997).
Like other living things, cells die, and new cells will be produced by the body. Normally cells
divide faster in early ages and allow the body to grow. After a person reaches adulthood, cell
division happens only to replace the dying cells.
DNA is the genetic material of a cell, and it controls growth and cell division. Sometimes
when the DNA becomes damaged, cell division and growth go out of control, and that can lead
to accumulations of extra cells called tumors. Abnormal cells or cancer cells can spread to other
body parts through the blood or lymphatic systems. Spreading cancer into other parts of the body
is called metastasis (National Cancer Institute [NCI], 2015). Not all tumors are cancerous.
Tumors can be divided into two types, benign tumors, and malignant tumors. Benign tumors are
not cancerous and do not invade other parts of the body. Malignant tumors are cancerous, and
they are able to attack other parts of the body. Cancers can be divided into different categories,
and the main categories are as follows:


Carcinoma: Cancer that begins in the skin or in the tissues that cover the other organs in
the body is called carcinoma cancer.



Sarcoma: Cancer that originates from bone, fat, muscle, blood vessels, cartilage, or other
connective tissues is called sarcoma.



Leukemia: Cancer that begins in the bone marrow is known as leukemia. Bone marrow is
a blood-forming tissue, found in the center of the bones, and it produces blood cells.
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Lymphoma and Myeloma: These are cancers that affect the immune system.



Central nervous system cancers: These are cancers that are related to the brain and spinal
cord (NCI, 2015).
The cancer risk assessment can be used to determine the level of risk for each individual.

Many family history factors can give details about cancer risk. Identifying cancer with genetic
testing can be used for treatment and for other prevention methods for patients. Therefore, cancer
risk assessment and testing can be useful in personalizing therapies to improve the outcomes of
the treatments (Riley et al., 2012). Cancer risk assessment is composed of many factors,
including personal and family health history, reproductive history and hormone use,
environmental risk factors, lifestyle and genetic information (Aiello-Laws, 2011). An accurate
risk assessment directs the proper use of cancer screening, risk reduction, genetic testing and
early detection strategies. It is also important to asses a complete medical and surgical history,
including current medications, lifestyle, environmental exposures, and congenital anomalies. If
the patient is a female, a detailed reproductive history is needed (Aiello-Laws, 2011). In order to
get a detailed assessment, we can use pedigree analysis, genetic testing, risk modeling,
biochemical testing and imaging, physical features, potential hereditary syndromes and cancer
risk assessment for a patient’s biological relatives. The information gathered can be used for
cancer screening, prevention, and risk reduction, and also for identifying cancer at-risk family
members (Riley at al., 2012).
1.2 What is Breast Cancer?
Breast cancer is a cancer that is found in breast cells. It is commonly found in women and
rarely in men. Female breasts are made up of milk-producing glands, lobules, and ducts that
carry milk from lobules to nipples. Ducts and lobules are covered with fatty connective tissue
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called stroma. Breast cancer that begins in the tissues of ducts is called ductal cancers, and
cancer that begins in the tissues of lobules is known as lobular cancer (American Cancer Society,
2014). Breast cancer can spread to other body parts through the lymphatic system. Lymph cells
are immune system cell that helps the cells to fight infections and foreign materials that enter the
body. A lymphatic system consists of lymph cells, lymph fluid, and lymph vessels that carry the
lymph around the body. Breast cancer cells are able to invade the lymph vessels and begin to
grow in the lymph nodes. The lymph vessels carry these cancerous cells to the other part of the
body, which is known as metastatic or secondary cancer (American Cancer Society, 2014).
The risk of developing breast cancer in women increases with their ages. The other
factors that increase the risk are hormone replacement factors, which include the use of hormone
replacement therapy (HRT), hormonal contraceptives, obesity, and alcohol. The risk is reduced
by different factors, which are being a young age at first childbirth, breast feeding, late menarche
and early menopause. The risk will double if the women have an affected first-degree relative
compared to women who don’t have a family history of breast cancer. High penetrance genes
such as BRCA1 and BRCA2 contribute high risk but only account for a small percentage of
breast cancer. The lifetime risk of breast cancer with BRCA1 accounts for 85%, and ovarian
cancer accounts 40% (Murray & Davies, 2013). However, the BRCA2 pathogenic variant shows
a little lower risk, especially for ovarian cancer, and it accounts less than 20%. For males BRCA
mutations contribute a risk for prostate cancer and breast cancer that is only 6 % (Murray &
Davies, 2013). Genetic information or family history can be identified using a family tree
diagram or pedigree analysis. Patients are assigned to one of the risk categories; women at or
near population risk of developing breast cancer, women at raised risk of developing breast
cancer and women at high risk of developing breast cancer. Many factors can be found in family
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histories that are suggestive of BRCA pathogenic variant. The clues include, multiple individuals
on one side of the family with breast or ovarian cancer, a young average age of diagnosis, male
breast cancer, associated cancer, and individuals with more than one primary cancer, including
bilateral breast cancer, and Ashkenazi Jewish Ancestry (Murray & Davies, 2013).
1.2.1 Factors that decrease the risk. The main risk factors that affect breast cancer
include age, gender, and mutation in breast cancer genes. A woman who started her first
menstrual period before the age of 12 is slightly at risk for breast cancer. The three hormones
that affect any woman in monthly menstrual cycles are estrogen, testosterone, and progesterone.
Estrogen level will be high in the body during the week of the menstrual cycle. Estrogen level
will be low after the menstrual days. Exposure of breast tissue to increased levels of estrogen
makes the women more at risk of developing breast cancer. Consequently, starting menstrual
period at an early age increases the risk of breast cancer (Centers for Disease Control and
Prevention [CDC], 2014).
Before menopause, estrogen is produced by the ovaries, and after menopause, estrogen
will be produced by fat tissue. Women who have menopause at an early age are less exposed to
estrogen. Giving birth to more children, giving birth to your first child at a young age, and
breastfeeding your children can also decrease the risk. Pregnancy and breast-feeding reduces the
risk of breast cancer as it reduces the women’s lifetime exposure to menstrual cycles and hence,
reduces exposure to estrogen level. Physical activity lowers the level of estrogen in the blood and
boosts the immune system of the body. Becoming obese after menopause may increase the risk
of breast cancer, as it increases the risk of estrogen receptor-positive breast cancer (CDC, 2014).
1.2.2 Factors that increase the risk. Long-term use of hormone replacement therapy:
Women use hormone replacement therapy to ease menopause. The hormones commonly
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prescribed in the therapy are estrogen and progesterone or progestin. Studies show that a woman
taking HRT has a high risk of developing breast cancer. If you have ever been diagnosed with
breast cancer, the recurrence of cancer in another part of the breast is always high. If you have
first-, second-, or third-degree relatives diagnosed with breast cancer, the risk of inheriting the
mutated gene is always possible, and that makes you at risk. In rare cases, radiation can cause
secondary breast cancer. Diethylstilbestrol is a form of estrogen hormone. This hormone was
prescribed to women to avoid miscarriage, premature labor, and related pregnancy problems
between 1940 and 1971. Different studies (Palmer et al., 2002) show that the women who have
received DES are more at risk of breast cancer when compared with women who never had DES.
Women who have high breast density are more at risk than women who have less breast density
(CDC, 2014). Alcohol increases the level of estrogen and other hormones relate to hormonereceptor- positive breast cancer. During the night, our body produces the hormone melatonin that
makes us feel sleepy and want to a rest. Exposure to artificial light, during the night, may reduce
the level of melatonin. As a result, it causes the body to produce more estrogen and makes
people at risk of breast cancer.
1.3 Problem Statement
According to Mayo Clinic, after skin cancer, breast cancer is the most common cancer
diagnosed in women in the United States. We have chosen breast cancer mutation risk, as breast
cancer is considered one of the leading causes of cancer deaths in women. As a common cancer
in women, are we able to predict the risk of carrying mutated genes based on the family history?
Family history can be considered one of the important risk factors for many chronic diseases.
The cancer risk assessment includes a complete personal medical history and previous
generations’ medical history to the extent that they are available. Family history helps to identify
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higher risk for some diseases and also helps to get an idea about early warning signs of diseases.
Does family history play an important role in predicting hereditary cancers? There are different
models available to the public to check breast cancer risk. Can we completely depend on these
prediction models to analyze the mutation risk? Do these models analyze complete family
history and other non-hereditary factors that affect sporadic breast cancer such as birth control,
hormone therapy, breastfeeding, drinking alcohol, and physical activity? In hereditary breast
cancer, the gene passes to the next generation through an autosomal dominant inheritance
pattern. Every child inherits two copies from their parents; one from their mother and one from
the father. As BRCA1, BRCA2, Tp53, and PTEN genes exhibit autosomal inheritance pattern;
there are four possible combinations for the child’s gene copy. By analyzing the inheritance
patterns, how can we predict the risk of carrying mutated genes in the offspring?
The aim of this research is to develop a software tool to predict the risk of hereditary
breast cancer in any living person and also in their children. The backbone of this software
program is NCCN guidelines. The existing tools to check the hereditary breast cancer are only
considering BRCA1/BRCA2 genes. Some of the tools are not considering family history. In this
research, we have included PTEN and Tp53 genes and also considered first-, second-, and thirddegree relatives. NCCN guidelines are the most thorough, comprehensive, up-to-date, and
reliable recommendations and are from a group of worldwide clinical practitioners.
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CHAPTER 2

Literature Review
2.1 Recent Breast Cancer Statistics
There are more than two hundred types of cancers that are recognized in the human body.
Nowadays, study and research about cancer is on the rise for various reasons. The World Health
Organization estimates significant growth in cancer patients worldwide and that cancer is poised
to overtake heart disease as the world’s top killer. According to the American Cancer Society,
the most common type cancer is breast cancer, with about 235,000 new cases expected in the
United States in 2014 (American Cancer Society, 2015). The following table shows the
estimated numbers of new cases and death for each common cancer.
Table 1
Breast Cancer Statistics
Cancer Type

Estimated New Cases

Estimated Deaths

74,690

15,580

232,670 – 2,360

40,000 – 430

Colon and Rectal (Combined)

136,830

50,310

Endometrial

52,630

8,590

63,920

13,860

Leukemia (All Types)

52,380

24,090

Lung (Including Bronchus)

224,210

159,260

Melanoma

76,100

9,710

Non-Hodgkin Lymphoma

70,800

18,990

Bladder
Breast (Female – Male)

Kidney (Renal Cell and Renal
Pelvis) Cancer
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Table 1
Cont.
Pancreatic

46,420

39,590

Prostate

233,000

29,480

Thyroid

62,980

1,890

In the United States 12% (one in eight) of women are at risk of invasive breast cancer
during their lifetime (Breastcancer.org, 2014). About 62,570 new cases of non-invasive breast
cancer have been reported in the United States. Breast cancer incidence rate was decreased from
the year 2002 to 2003 after the decrease in the use of hormone replacement therapy. The study
shows a large decrease in the death rate after 1989, and it is thought to be the result of early
detection and prevention. However, the death rate is higher than any other cancer except lung
cancer. White women have more probability to develop breast cancer than African American
women. However, breast cancer under the age of 45 is more prevalent in African American
women than white women. Asian, Native American, and Hispanic women have a lower risk of
developing breast cancer. In 2014, recent data shows 2.8 million women are identified with
breast cancer, which includes women who are undergoing treatment and who finished treatment.
Among women with breast cancer, 15% have a family history of breast cancer (American Cancer
Society, 2015).
2.2 Open Source Cancer Risk Assessment Tools
There are many software programs available to assess breast cancer risk and screening.
Early detection of breast cancer helps to make a decision about the prevention of the cancer.
None of the tools are accurate. However, it gives an understanding of breast cancer risk based on
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your habits and family history. These programs have many features and limitations. One of the
main drawbacks of all the programs is, none of the tool takes all risk factors associated with
breast cancer. Each tool calculates only an estimated result based on the risk factors it considers.
As there is no comprehensive breast cancer risk assessment tool, it is advisable to consider other
health care assist to detect breast cancer earlier. Before checking the risk, try to use a reliable and
credible program that has been created by a faithful source. Select a tool that provide the features
and limitations of the tool, and understand how it was developed.
2.2.1 Gail model – Breast cancer risk assessment tool. This program has been
developed (http://www.cancer.gov/BCRISKTOOL/) by scientists at the National Cancer Institute
(NCI) and it is periodically updated with new data. The Gail model is used to calculate invasive
breast cancer risk over a five year period and a lifetime period (Gail et al., 1999). This tool is
useful for healthcare providers to assess the breast cancer risk and also help to make decisions in
prevention strategies. This tool mainly focuses on non-genetic factors, personal history, previous
breast biopsies, age of menarche, age of first live birth and family history of first-degree
relatives. The main drawbacks of the program are, it does not consider other breast cancerrelated factors such as breast density, hormone replacement therapy, breastfeeding, smoking, age
at menopause and alcohol consumption.
2.2.2 IBIS tool. The IBIS tool (http://www.ems-trials.org/riskevaluator/) is used to
calculate a person’s likelihood of carrying the BRCA 1 or 2 mutations, which are associated with
increased breast cancer risk. It estimates the likelihood of a woman developing breast cancer in
ten years and over the course of her lifetime. The tool is used to help inform a person’s decisionmaking about genetic counseling and testing.
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The IBIS tool is developed based on the Tyrer-Cuzick model and it predicts a person’s
risk of carrying BRCA1 or BRCA2 genes. It calculates the risk of developing breast cancer over
ten years and a lifetime period based on the estimation of BRCA1/BRCA2 genes. It is a good
breast cancer decision-making tool. It considers many risk factors such as age, age at first live
birth, body mass index, hormone replacement therapy, age at menopause, and family history.
This tool suggests genetic counseling if the risk is 10% or higher. The disadvantages of the tool
are that it does not consider breast density, alcohol consumption, oral contraceptive pill use, etc.
2.2.3 Myriad II. Myriad II (http://www.myriadpro.com/brca-risk-calculator/calc.html)
has been developed based on empirical data which was conducted among ten thousand women
with germline mutations in BRCA1/BRCA2 genes. The Myriad II prevalence tables (Frank et al.,
1998) are based on proband and family history (van et al., 2010). The tool considers different
risk factors such as relatives with ovarian cancer at any age, relatives with breast cancer, age of
the relatives, and male breast cancer. It allows only a maximum of three relatives and does not
give separate result for BRCA1 and BRCA2. It gives a separate analysis for Ashkenazi Jewish
Ancestry.
2.2.4 BOADICEA web application (BWA). The BOADICEA is another tool, and it has
collaborated with MENDEL, (http://ccge.medschl.cam.ac.uk/boadicea/advice-for-the-public/)
which is pedigree software used to estimate the risks of breast and ovarian cancer in women. It
calculates the probability of BRCA1 or BRCA2 genes. It also predicts the possibility of a woman
developing breast cancer in five years and in her lifetime. The tool uses family history and gene
mutation risk to calculate the risk of breast cancer. The tool recommends genetic counselling if
the risk is 10% or higher. This tool only considers mutation status and family history. It doesn’t
consider any other non-genetic factors. The tool was developed based on data from the United
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Kingdom. Therefore, the calculation will have less accuracy for other people from other
countries.
2.2.5 PENN II. It is a free web-based tool (http://www.afcri.upenn.edu/itacc/penn2/), and
it uses logistic regression based on pedigrees from Europe and North America. The tool
considers age at onset of breast cancer, ovarian cancer, bilateral breast cancer, pancreatic cancer,
and prostate cancer. The results of the program contain both BRCA1 and BRCA2 mutations. The
results don’t contain breast cancer risk, and it recommends genetic testing for people with 5% or
higher risk. It gives a one-page questionnaire, and the tool considers first-, second-, and thirddegree relatives. It excludes proband from families with no breast cancer.
2.2.6 Breast cancer surveillance consortium risk calculator. The Breast Cancer
Surveillance Consortium (BCSC) risk calculator was created by scientists who participate in
Breast Cancer Surveillance Consortium (https://tools.bcsc-scc.org/BC5yearRisk/intro.htm). This
model gives a calculation of women’s risk over a five-year time period. The tool was designed
for health care professionals. The tool does not consider previous diagnosis of breast cancer,
lobular carcinoma in situ, ductal carcinoma in situ, atypical ductal hyperplasia, or breast
augmentation. This tool only considers people who are between the ages of 35 and 79. The
model focuses on age, race, ethnicity, family history of first-degree relatives, history of breast
biopsy, and breast density.
2.2.7 Hall detailed breast risk calculator. This open source breast cancer risk calculator
was designed by Dr. Halls (http://halls.md/breast/risk.htm). This risk assessment tool includes
many factors that are not included in the Gail model. This tool underestimates various factors
such as two or more people in the same generation with the same cancer, breast cancer before the
age of 50, ovarian cancer, cancers in both breasts, and melanoma. The tool includes first-degree
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relatives, breast biopsies, age at menarche, age at first live birth, current age, and race. The result
of the estimation falls into different categories. It gives the risk over five years, ten years, twenty
years, thirty years, and a lifetime period.
2.2.8 Bright Pink. Bright Pink is (http://www.brightpink.org/knowledge-ispower/assess-your-risk/) another open source tool that calculates breast cancer risk. It is designed
for academic use. This tool considers first- and second-degree relative breast cancer history, age
at onset of breast cancer, multiple breast cancers, male breast cancer, ovarian cancer, other
related cancers, and known mutations. The tool also considers non-genetic factors such as body
mass index, alcohol consumption, smoking, physical activity, diet, birth control pills, and age at
first live birth. The result is given in a PDF format.
The above open source programs have many limitations. These tools are only considering
BRCA1 and BRCA2 mutations. None of the existing breast cancer tools available considers
other high-risk genes such as PTEN and Tp53. Many of the existing tools are proprietary and not
available to the public. Most of these existing tools have been developed based on the data
collected from a particular demography or ethnicity. Many of the tools available do not consider
third-degree relatives and family history.
2.3 Role of Family History in Breast Cancer Risk Assessment
Family history can be considered one of the important risk factors for many chronic
diseases. The cancer risk assessment includes a complete personal medical history and previous
generations’ medical history to the extent that they are available. We have developed a family
history diagram, as shown in Figure 1, with the help of the US Department of Health and Human
Service website (HHS, 2014).
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Figure 1. Family health portrait.
The diagram helps a person to store his/her entire family history as a report or a diagram.
The diagram assembles all information to make a pedigree analysis and give a family tree based
on health records. It helps to identify the higher risk for some diseases and also helps to get an
idea about early warning signs of diseases (HHS, 2014). This health information can be stored in
HealthVault, and it will be accessible to the person at any time. In this project, this family history
diagram makes it easy to develop the program based on pedigree analysis.
Figure 1 describes the entire family history of a person that includes history of the
deceased people and the reasons for death. It gives an overall idea about a person’s family health
history that includes parents, grandparents, and first-degree relatives. It will be helpful to analyze
if a person has any risk of cancer. If this family history diagram contains any repeated diseases
among first-degree or second-degree relatives, the chances of getting the disease in the next
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generation are high. Many family history factors can give details about hereditary diseases such
as cancer, diabetics, heart attack, and asthma.
Family history is an essential component of any cancer risk assessment. Family history
tool must be simple, easily applied and inexpensive, and should be capable of identifying a
person according with the intensity of the diseases and positively influencing healthy behaviors.
When it comes to chronic diseases such as cancer and cardio vascular disease, family history
reflects hereditary factors, environmental, cultural and behavioral factors (Yoon, Scheuner, &
Khoury, 2003). A typical family history should be obtained from the proband. For each
individual, specifically biological relationships among family members, ages, causes of death,
genetics, surgical history, and any other medication should be marked. Hereditary cancer is
associated with highly penetrant genes, and it reflects the range of risk associated with a
mutation in the gene. Penetrance data from families with single gene mutation hereditary cancer
syndromes are revised as modifier genes. Oncology professionals should reassess the family
history, as family histories are dynamic. Accuracy of risk assessment can be affected by different
factors (Aiello-Laws, 2011). The cancer risk assessment can be used to determine the risk level
for each individual. Based on the family history, if an individual has a suggestive inherited
cancer syndrome, a genetic testing can be carried out to detect the repeated cancer present in the
family. The risk assessment includes a complete personal medical history and previous
generations’ medical history, if available. A standardized pedigree nomenclature and wellprepared questions are important factors in assessing the risk. Before starting questionnaires,
preparing a family health history portrait of the individual will help in the risk assessment (Riley
et al., 2012). Genetic tumor or cancer risk assessment reveals the possibility of DNA alterations,
which are strong causes of cancer. Genetic risk assessment involves identifying and counseling
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individuals at increased risk for cancer development and distinguishing the intensity of cancer.
Genetic testing can be considered when an individual has a family history of genetic cancer
susceptibility. Genetic testing is most useful when initiated when the person with cancer
concerns is diagnosed at a young age. The test should begin by testing for the syndrome that the
individual’s features most resemble (Aiello-Laws, 2011). In order to get a detailed assessment,
we can use pedigree analysis of the entire family. The information gathered could be used for
cancer screening, prevention, and risk reduction, and also for identifying cancer at-risk family
members (Lalloo & Evans, 2012).
Family health history is a significant cause that increases a person’s risk of developing
breast and ovarian cancer. Every individual should be mindful of these risk factors in his/her
family. In general, the number of first-, second-, or third-degree relatives who have or had breast
or ovarian cancer, and the age at onset of their diagnosis, increases the person’s breast cancer
risk. If you have a first-degree relative (sister, brother, father, son, or daughter) identified with
breast cancer, the risk will be doubled (breastcancer.org, 2014). At the same time, if you have
two first-degree relatives, the risk will be five times higher than the average. In many cases,
family history of breast cancer is related to abnormal genes such as BRCA1, BRCA2, PTEN, and
Tp53.
Different studies among families show that many women developed breast and/or ovarian
cancer together. A majority of the cases are reported at earlier than usual ages. Medical
practitioners suggested the term Hereditary Breast and Ovarian Cancer Syndrome (HBOC) after
the analysis in many families. The mutation in genes BRCA1 and BRCA2 are the main causes of
this disease. Even though mutations in either gene can cause the risk, the BRCA1 mutation
causes a higher risk of breast cancer. The BRCA2 mutation is more likely related to male breast
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cancer, pancreatic cancer, and prostate cancer. The BRCA gene mutation is common in people
who belong to Ashkenazi Jewish families. There are other hereditary diseases such as Cowden
syndrome (gene Tp53 mutation) and Li-Fraumeni syndrome (PTEN gene mutation) that have a
high impact on breast cancer (American Cancer Society, 2014).
Women with a family history of breast/ovarian cancer can go through genetic counseling
to calculate the risk of mutation in one of the BRCA genes. The professional will estimate the
risk based on the personal or family history of cancer. After the estimation, if a mutation is
present, the woman would have a high risk of breast/ovarian cancer. The calculation helps the
person to find cancer early, and it will lower the risk of getting cancer. If the person is at risk of
hereditary breast/ovarian cancer, it means that their close relatives have a 50% chance of having
the same kind of mutation.
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CHAPTER 3

Different Models to Predict Breast Cancer
Breast cancer risk assessment models help people in determining the risk. Medical
practitioners use different models to assess the patient’s risk of developing breast cancer. All the
breast cancer tools that are available now have many drawbacks, and the accuracies of these
models are not perfect. These models assess the risk either as the probability of developing breast
cancer or the probability of mutated genes that cause breast cancer. It is important to assess the
risk very accurately to make the right steps in prevention strategies, which range from lifestyle
changes to breast removal. It is required to develop an accurate model to assess individual risk.
The accuracy of the models depends on many factors such as lifestyle, diet, and hereditary
history. However, breast cancer is likely to occur even in the absence of these known factors.
This chapter discusses different breast cancer risk assessment models and also compares
different models.
3.1 Gail Model
The Gail model was developed by Dr.Mitchell Gail, a senior investigator in a biostatistics
department. The risk factors considered for the Gail model were age at menarche, age at first live
birth, number of previous biopsies, and the number of first-degree relatives with breast cancer.
The model is based on the relative risks of various combinations of these factors taken from the
Breast Cancer Detection Demonstration Project (BCDDP). The cases used for this model
consisted of women with breast cancer between 1978 and 1980 at twenty-nine participating
centers that involved 280,000 women aged 35 to 74 years. This model groups the patients into
two categories based on their age. The relative risks connected with previous breast biopsies
were smaller for women of age 50 and older than women younger than 50. The model, again, is
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subdivided into three parts: (a) Estimating the relative risk for a subject with a given group of
risk factors at a given age compared to a subject without the identified risk factors; (b) estimating
the baseline age-specific breast cancer hazard rate, which is the rate for a woman without
identified risk factors; and (c) projecting the long-term probability of developing breast cancer
on the basis of a consideration of competing risks and the results on relative risk and baseline
hazard (Gail et al., 1989). The model does not consider many medications such as oral
contraceptives, thyroid supplements, rauwolfia preparations, and diazepam medications. Other
habits such as cigarette smoking and methylxanthines have not been considered in the analysis.
The other major factors that the Gail model does not include are body mass index, age at
menopause, breast feeding, plasma estrogen, lobular carcinoma, breast density, second-degree
relatives, third-degree relatives, ovarian cancer, and male breast cancer. This model is validated
only for white women. The model has been tested in African American women and Asian and
Pacific Islander women, and it underestimates the risk in African American women with
previous breast biopsies. The data for African American women has been collected from the
Women’s Contraceptive and Reproductive Experiences (CARE) and from SEER data. The data
for Asian and Pacific Islander women has been collected from the Asian American Breast
Cancer Study and SEER data. In order to improve the model, various studies have been
conducting in Hispanic and other minor community women.
3.2 Claus Model
In the Claus model, the risk is calculated based on an autosomal dominant genetic model.
The likelihood of this model is calculated from a joint analysis of mothers and sisters of the
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white cases and controls. “The likelihood for the mother of a case was calculated conditional
upon the age at onset of the case. For mothers of controls, the likelihood was calculated
conditional upon the current age of the control. The likelihood for sisters of cases was calculated
conditional upon the breast cancer status of the mother as well as the age at which the case was
affected. The age at which a mother with breast cancer was affected, or, in the instance of an
unaffected mother, her current age or age at death was also incorporated into the sister’s
likelihood. For sisters of controls, the likelihood was calculated in the same fashion with the
exception that current age on control was substituted for age at onset of case (Claus, Risch, &
Thompson, 1993).
The Claus model is widely used in research studies and clinical counseling. The data used
in the Claus model is derived from the Cancer and Steroid Hormone Study. The case-control
study is conducted by the Centers of Disease Control. There were 4,730 cases analyzed in the
ages of 20 to 54 years, and 4,688 controls were matched to cases on the basis of both geographic
regions and five-year categories of age (Claus, Risch, & Thompson, 1991). Family histories are
obtained through interviews on different cases about breast cancer. The Claus model considered
first- and second-degree relatives and age of onset of relatives. The model incorporates paternal
and maternal family history and family history of ovarian cancer. The major limitations of the
Claus model are that it may underestimate risk in hereditary families, may not be applicable to
all combinations of affected relatives, and does not include risk factors other than family history.
The model is best fit for individuals with no more than two first-degree relatives or seconddegree relatives with breast cancer.

24
The Gail model and Clause model underestimate women from hereditary breast cancer
families. This model is not a sole model for the families that have the following characteristics
(NCI, 2015).
 Three individuals with breast or ovarian cancer diagnosed before the age of 50


Women who have both breast and ovarian cancer



People who belong to Ashkenazi Jewish ancestry with at least one case of breast or
ovarian cancer
The Claus model assesses the probability of a woman developing breast cancer based on

family history. However, it does not consider other risk factors such as bilateral breast cancer,
male breast cancer, and ovarian cancer. The Claus model risk can be calculated as lifetime risk or
an estimated risk over a ten-year period. The Claus model only considers first- or second-degree
relatives, and it does not consider third-degree relatives. In addition, it does not include nonhereditary risk factors.
3.3 BRCAPRO Model
The BRCAPRO model is statistical model associated with software (CancerGene v5.1) to
measure the risk of germline deleterious mutation of BRCA1 and BRCA2 genes. This model was
developed based on Mendelian approach, and it assumes autosomal dominant inheritance for
BRCA1/BRCA2 genes. The model was originally developed in 1995 to 1999 by Parmigiani and
colleagues, and it was later modified in 2007. The initial study sample consisted of 292 families
that included at least one person tested for BRCA mutation. The family group included 104
African American, 130 Hispanic, 37 Asian American, and 21 other minority families. The
families have been identified mainly through two sources. The information for the first group is
collected from the Breast Cancer Registry Family (BCFR). The second group was identified by
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the Cancer Risk Clinic at the University of Chicago. The information about Ashkenazi families
was not included initially and later had been added to the model. The major features that are
included in the model are first-degree relatives, second-degree relatives, age of onset of breast
cancer, bilateral breast cancer, ovarian cancer, and male breast cancer. This model considers both
affected and unaffected relatives. This model gives an estimated result for either BRCA1 or
BRCA2 mutation risk. The model computes the breast cancer risk based on the likelihood of
BRCA1 or BRCA2 mutation risk. None of the non-hereditary factors such as alcohol intake, age
at menarche, oral contraceptive pills use, and breast feeding are incorporated into this model.
According to the study done by the Family History Clinic at the University Hospital of South
Manchester, this model has the least accuracy in breast cancer risk assessment compared with the
Gail, Claus, and Tyrer-Cuzick models (Amir et al., 2003). The model performed best in
Hispanics (highest AUC- 0.83) and worst for African American families (AUC-0.68), and it
provided intermediate result for other minority groups, mainly Asian-America and Native
Americans (AUC-0.71) (Huo et al., 2009). This model appears to be worthy in predicting
mutation risk in male patients.
Advantages of BRCAPRO model (Petrucelli, Daly, & Fledman, 2010):


Estimates probability of mutation in BRCA1/BRCA2



Considers Ashkenazi Jewish Heritage



Frequently updated



Provides printout for pedigree analysis



Considers both affected and unaffected relatives

Drawbacks of BRCAPRO model:


Analysis has been done based on high-penetrance families
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Considers only first- and second-degree relatives



Needs CancerGene software and data entry for each family
The BRCAPRO model performs well in pretest prediction of BRCA mutation, especially

in minority communities and Hispanic families, maybe because they are genetically closer than
other white populations.
3.4 Cuzick-Tyrer Model
The Cuzick-Tyrer model was designed to predict ten-year risk of breast cancer
development using genetic and non-genetic risk factors. The Cuzick-Tyrer model is the most
reliable and accurate model for prediction of breast cancer. The Cuzick-Tyrer statistical model
calculates the risk of breast cancer by considering many factors such as family history, age at
menarche, parity, age at menopause, atypical hyperplasia, age at first childbirth, height, lobular
carcinoma in situ, and body mass index. The program assumes that there are other genes that
influence breast cancer other than the BRCA genes. The patient’s family history is used to
estimate the probability of carrying a faulty gene that affects the possibility of developing breast
cancer. The data for the model has been collected from the International Breast Intervention
Study and other epidemiological data. According to different studies, the Cuzick-Tyrer model is
the best model to assess breast cancer risk, as it is integrated with family history, estrogen
exposure, and benign breast diseases. The risk factors of the individual are collected through
questionnaires and through a review of medical records. A separate analysis has been done for
women with atypical hyperplasia, as this disease has a high risk of breast cancer. Among 9,376
patients, 331 women were identified with atypical hyperplasia (Boughey et al., 2010). This
model advises genetic counselling when the risk level of BRCA1/BRCA2 is 10% or higher. The
IBIS tool (http://www.ems-trials.org/riskevaluator/) is the software tool that has been developed
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based on the Cuzick-Tyrer model. The tool does not include risk factors such as lifestyle, breast
density, and third-degree relatives. The key benefit over the Claus model and the BRCAPRO
model is that the Cuzick-Tyrer model permits the presence of multiple genes of different
penetrance levels. The algorithm for this model produces information of BRCA1/2 along with
lower penetrance of BRCAX. The model incorporated women who have a single first-degree
relative affected by breast cancer. This model also considers ovarian cancer history, as ovarian
cancer has a significant effect on breast cancer. The Cuzick-Tyrer model also accurately predicts
risk in women whose menarche appeared after the age of 12 years. Even though the model is
more powerful than other models at the current time, it is less available to primary care providers
than other models.
3.5 BOADICEA Model
The Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm
(BOADICEA) is a statistical model used to compute the risk of hereditary breast and ovarian
cancer. This model uses the BRCA1/BRCA2 mutation probabilities to calculate the risk of
breast/ovarian cancer. The model was developed based on 2,785 families and has been validated
in a large series of families from UK genetics clinics. There are some limitations related to the
first version of BOADICEA. “The model assumed that a fixed set of calendar period incidences
applied to all cohorts, when breast cancer incidences have been increasing over time. As part of
the model-fitting process, we also estimated the BRCA1 and BRCA2 breast and ovarian cancer
risks, but these were based on a relatively small number of mutation-carrying families and were
therefore imprecise” (Antoniou et al., 2008). To calculate the risk, BOADICEA considers the
family history of breast, ovarian, prostate, and pancreatic cancer. A new version of BOADICEA
has included specific incidents of these cancers from different countries. This model uses the
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Mendalian approach to analyze the pedigree of the family history (Lee et al., 2014). The model
does not include non-hereditary factors such as age at menopause, alcohol intake, contraceptive
pill use, or body mass index. MENDEL is a breast cancer prediction software program that has
been developed based on BOADICEA, and it is useful for families of an arbitrary size and
structure. The model was developed based on families which are mainly from the UK, and it also
included a few families from Sweden. The model was created for invasive breast cancer and is
less accurate for ductal cancer in situ (DCIS).
This model groups people who were born in a particular period, and it analyzes the breast
and ovarian cancer risk for each person developing cancer during a particular time. The
estimated population frequency for the BRCA1 mutation was 0.06% and for the BRCA2
mutation was 0.10% (Antoniou et al., 2008). The model calculates breast cancer risks in BRCA1
and BRCA2 carriers on a birth cohort effect, and the risk increases in more recent birth cohorts.
For example, women who born in 1920–1929 show an average cumulative breast cancer risk of
50%, and it is 58% for women born after 1950.
3.6 Comparison of Different Models
The main drawbacks of the Gail model is that it does not consider second- or third-degree
relatives to assess the risk and mainly focusing on non-genetic factors. In addition, this model
does not count age of onset of breast cancer, bilateral breast cancer, ovarian cancer, and male
breast cancer, and it does not calculate the risk of getting breast cancer in the subsequent time.
The Gail model measures risk based on patient age, age at menarche, number of prior breast
biopsies, age at first live birth, and number of first-degree relatives affected by breast cancer
(Evans & Howell, 2007). The tool is designed for health professional such as doctors and nurses.
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Therefore, the terms and explanations might not be easy to understand for people who have less
knowledge about breast cancer.
Table 2
Comparison of Different Models
Factors considered

Gail model

Age (20–70 years)
Body mass index
Alcohol intake (0–4
units) daily
Age at menarche

Yes
No

Claus
model
Yes
No

BRCAPRO
Cuzick–
model
Tyrer model
Yes
Yes
No
Yes

BOADICEA
model
Yes
No

No

No

No

No

No

Yes

No

No

Yes

No

Age at first live birth
Age at menopause
Hormone
replacement therapy
oral contraceptive
pill use

Yes
No

No
No

No
No

Yes
Yes

No
No

No

No

No

Yes

No

No

No

No

No

No

Breast feeding

No

No

No

No

No

Plasma estrogen
Breast biopsies
Atypical ductal
hyperplasia
Lobular carcinoma
in situ
Breast density
First-degree relatives
Second-degree
relatives
Third-degree
relatives
Age of onset of
breast cancer
Bilateral breast
cancer
Ovarian cancer
Male breast cancer

No
Yes

No
No

No
No

No
Yes

No
No

Yes

No

No

Yes

No

No

No

No

Yes

No

No
Yes

No
Yes

No
Yes

No
Yes

No
Yes

No

Yes

Yes

Yes

Yes

No

No

No

No

Yes

No

Yes

Yes

Yes

Yes

No

No

Yes

Yes

Yes

No
No

No
No

Yes
Yes

Yes
No

Yes
Yes
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The Cuzick-Tyrer model and the Claus model are developed based on family history that
includes first- and second-degree relatives. These tools are not available to the public and are
generally made for medical professionals (R. Ellsworth, Decewicz, Shriver, & L. Ellsworth,
2010). Neither of these tools considers male breast cancer history. The Claus model is not linked
to important family history factors such as bilateral cancer and ovarian cancer. The Claus and
BRCAPRO models were developed fifteen to twenty-five years ago, and worldwide breast
cancer incidence has increased by more than 20% since 2008. Therefore, the risk estimates based
on lower-risk populations underestimate the current risk. The BOADICEA model is only
predicting the risk of BRCA1/BRCA2 mutation (Ellsworth et al., 2010). It does not count other
potential genes such as PTEN or Tp53 for the studies.
The Claus and Gail models are mainly used in research studies and clinical risk
assessments. The discriminatory accuracy and best fit of the Gail, Claus, BRCAPRO, and
Cuzick-Tyrer models have been calculated taking data from 1,933 women attending the Family
History and Screening Program in the UK. These models are implemented to estimate the breast
cancer risk assessment in women over a follow-up of five years. The ratio of the expected to
observed cases of breast cancers was 0.48 for the Gail model, 0.56 for the Claus model, 0.49 for
the BRCAPRO model, and 0.81 for the Cuzick-Tyrer model. The accuracy for each model has
been developed separately, and the AUC (Area Under the Curve) for the Gail model was 0.735,
for the Claus model was 0.716, for the BRCAPRO was 0.737, and for the Cuzick-Tyrer model
was 0.762 (Evans & Howell, 2007). The Cuzick-Tyrer model was the most consistent and
accurate model. The Claus, Gail, and BRCAPRO models significantly underestimated the risk,
especially with people who had a single first-degree relative with breast cancer. The Claus model
gives better accuracy if it is manually adjusted for the risk factors. The Cuzick-Tyrer and manual
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models were accurate in this case. However, all models accurately predicted the risk in people
with multiple relatives diagnosed with breast cancer. The Gail model was less accurate in
predicting risk with a single first-degree relative, as it does not count the age at onset of the
cancer. The BRCAPRO and Cuzick-Tyrer models were the only accurate models which have
approximately similar values to the manual model in perdition of risk with a family history of
ovarian cancer. This is the only model which considered ovarian cancer history to predict the
breast cancer risk. The Gail, Claus, and BRCAPRO models underestimated the risk in women
regarding age of first birth, and these models underestimate the risk factor in women whose
menarche appeared after the age of 12 years (Evans & Howell, 2007). The BOADICEA model
has almost the same approximate prediction value as the Claus and BRCAPRO models. The
BOADICEA model is a polygenetic model, and it examines the risk of BRCA1/BRCA2
mutation along with breast cancer risk. The BRCAPRO and BOADICEA models have high
diagnostic accuracy in predicting the mutation risk of BRCA1/BRCA2, and the BOADICEA
model has been further modified with tumor markers (ER), progesterone receptors (PR), and
human epidermal growth factor receptor 2 (HER2) (Biswas et al., 2012; Tai, Chen, Parmigiani,
& Klein, 2008). The limitations of the models are the strength of the research data, the
population used, and the overestimation in gene harboring (Aiello-Laws, 2011).
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CHAPTER 4

Analyzing Hereditary Information in Predicting Breast Cancer
There are some particular features that may predict the possibility of a hereditary cancer
syndrome associated with a single gene mutation. The main features of hereditary cancer
syndromes are a family member with more than one cancer, patterns of autosomal dominant
transmission, bilateral cancer, rare cancer, precursor lesions, male breast cancer, ovarian cancer,
and breast cancer. The information collected can be used to determine whether the cancer in an
individual or family is associated with an inherited predisposition and to establish the most likely
differential diagnosis (Aiello-Laws, 2011).
The presence of mutated breast cancer genes is detectable in current or future generations
based on the information gathered from family history. Family health history plays a major role
in determining the risk factors, as it gives a link to hereditary, environmental, cultural, and
behavioral factors of the entire family (Yoon et al., 2003). The risk factors involved in breast
cancers are age, gender, genetic factors, family history, race/ethnicity, and habits. Breast cancer
occurs more often in females than in males because of the female hormones like estrogen and
progesterone, which help cancer cell growth (American Cancer Society, 2014). This section
analyzes the different genes that are considered for the prediction of breast cancer. The risk of
developing breast cancer increases with age. Many factors can be found in a family history that
is suggestive of BRCA pathogenic variant. The clues include, multiple individuals on one side of
the family with breast or ovarian cancer, a young average age of diagnosis, male breast cancer,
associated cancer, individuals with more than one primary cancer, including bilateral breast
cancer, Ashkenazi Jewish Ancestry (Murray & Davies, 2013).
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4.1 Discussion on Gene Affecting Breast Cancer

Figure 2. Cell, chromosomes and DNA.
Proteins are large molecule that plays important role in our body. Proteins help the cell to
work properly. The proteins are made up with amino acids. There are different kinds of amino
acid that together make a protein molecule. The particular sequencing of amino acids make a
specific function to each protein. Genes are made up with these different functional molecules
(protein) and also it is a part of DNA. A gene is a segment of DNA that is inherited from parents
to children, and it determines the traits of the offspring. Every gene has different functions, such
as embryo development, cell growth, personality, eye color, or metabolism. DNA is a molecule
that stores the genetic information of any living organisms.
DNA is a molecule that contains nucleotides which are the building blocks of DNA. A
nucleotide is made up of a phosphate group, a sugar group and a nitrogen base. RNA or
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ribonucleic acid is another type of nucleic acid, and it transfers genetic information from DNA to
a body cell.
Nucleotides are paired together and form a double helix structure. Each side of the double
helix is made up of the phosphate and sugar molecules and the nitrogen bases connect each side.
The chains are composed of four different nucleotides, namely Adenine, Guanine, Cytosine and
Thymine (Williams, 1997; National Library of Medicine [NLM], 2015). The order of these
chemical letters determines DNA's information or genetic information. The nitrogen bases are
always found in pairs; adenine pairs with thymine, and guanine pairs with cytosine.
Chromosomes are a spiral shaped form of DNA.
The DNA sequence can be mutated in many ways. The different kind of mutation
include, missense mutation, nonsense mutation, insertion, deletion, duplication and frameshift
mutation. Missense mutation occurs when a DNA base pair sequence change and that substitute
one amino acid for another. Nonsense mutation also occurs when the DNA base pair become
damaged. In nonsense mutation mutated DNA signals the cell to stop building protein. In
insertion mutation, DNA sequencing get altered by another piece of DNA. As a result the gene
may not function properly. Deletion mutation changes the DNA sequencing by removing a piece
of the DNA sequence. The deleted DNA cause malfunctions in protein synthesis. In duplication a
section of DNA is repeated accidently and thus makes the malfunction of the protein. Frameshift
mutation occurs when any changes occur in reading frame of DNA. A reading frame include
three bases and each base corresponds to one amino acid. When the frameshift mutation occurs it
shift these bases and thus amino acid get base that not supposed to have. As a result the protein
synthesis may go wrong. A short DNA sequence called Nucleotides are repeating many times in
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a DNA sequence row. Trinucleotide repeat 3 times and tetra nucleotide repeat four times. If this
chain is repeated unwanted or abnormally makes the protein malfunction.
DNA sequencing can be damaged by many mutagens such as oxidizing agents or
alkylating agents and by radiation like X-rays, UV rays, and electromagnetic radiation. Any
changes in the DNA sequence of the gene can cause genetic disease. Cancers can be hereditary,
and they pass the gene mutations to the next generations through a specific inheritance pattern.
Mutated genes such as BRCA1, BRCA2, Tp53, and PTEN confer high lifetime risk of breast
cancers (Lalloo & Evans, 2012). There are other genes such as PALB1, BRIP and LKB1 behind
breast cancer, which contribute moderate risk. However, BRCA1, BRCA2, TP53, and PTEN are
the most considered genes for clinical studies.
Medical information about other factors that cause cancers such as hormone level,
gender, lifestyle, diet, habits, pollution, and physical activity helps to predict non-hereditary
cancers in the current generation. We estimate the analytical validity of the information that is
gathered from the information by comparing it with the results that have been already determined
by scientists through experiments.
4.1.1 BRCA1 and BRCA2. Hereditary Breast or Ovarian Cancer Syndrome (HBOC)
hereditary genetic condition, and the genes associated with this syndrome are BRCA1 and
BRCA2 (BReast CAcer ). Most of the breast and ovarian cancers are not hereditary. Both the
BRCA1 and BRCA2 genes are responsible for protein involvement in tumor suppression.
BRCA1 is located on chromosome 17 and is involved in the repair and regulation of DNA
damage. The BRCA2 gene is located on chromosome 13 and is involved in DNA break and
repairs (Murray & Davies, 2013). Both genes exhibit high penetrance, ranging from 41% to 90%,
with increased risk of other related cancers such as ovarian cancer, epithelial cancer, pancreatic
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cancer, and prostate cancer. Male carries of the BRCA gene confer high risk of breast cancer,
especially if the gene is BRCA2. The risk of breast cancer increases if the person has close blood
relatives who have breast cancer. The risk increases as the number of affected relatives increase
and also varies in accordance with people’s race and ethnicity. A woman who is an Ashkenazi
descendant has more risk of developing breast cancer if she is a carrier of the mutated genes
BRCA1 and BRCA2.
It has been calculated that 90% of the early onset breast/ovarian cancer in families is
triggered by BRCA1/BRCA2 mutations (Murray & Davies, 2013). Therefore, the risk of
developing breast/ovarian cancer is relatively high if the individual has a personal or family
history of both cancers. The risk level of developing breast or ovarian cancers due to the
mutation of BRCA1/BRCA2 genes may vary even within families with same mutations
(Abeliovich et al., 1997; Pagon et al., 2013). The estimation can vary from a 41% to 90%
lifetime risk of breast cancer (Antoniou et al., 2003; Chen & Parmigiani, 2007; King, Marks, &
Mandell, 2003). A published study shows that the calculated risk of BRCA1 mutation indicates
that risk of developing breast and ovarian cancer is 57% and 40%, respectively. In the same
scenario with BRCA2, the risk is 49% and 18%, respectively (Chen & Parmigiani, 2007).
Several studies shows that 9% to 21% of BRCA1 mutation is more likely to be linked
with triple negative breast cancer (Atchley et al., 2008; Young et al., 2009). In addition to that,
BRCA1 mutation appears at early ages among people who have triple negative breast cancer
when compared with non-carriers (Gonzalez-Angulo, 2011; Lee, 2011). For a person with triplenegative breast cancer with a family history of breast/ovarian cancer, the risk of BRCA1
mutation was 48% (Fostira et al., 2012). Among Ashkenazi Jewish families, people who have
personal histories of triple-negative breast cancer had identified with 11% of BRCA1 mutations.
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Different studies show that triple-negative breast cancer is also associated with BRCA2
mutations (Comen et al., 2011). The risk of BRCA2 mutation related to personal history of
triple-negative breast cancer ranges from 4% to 17% (Comen et al., 2011). Germline mutations
of BRCA1 and BRCA2 mutations associated with prostate cancer, especially BRCA2 mutation,
are linked with two to six times’ higher risk (Agalliu, Gern, Leanza, & Burk, 2009; Kirchoff,
2004). Patients with prostate cancer due to BRCA2 mutations show decreased survival compared
with BRCA1 mutations (Thorne, 2011). BRCA2 mutation is also linked with a higher risk of
pancreatic and melanoma cancer than BRCA1 mutation. In addition, BRCA2 mutations have
more response with chemotherapy treatment when compared with BRCA1 or non-carrier cases.
Germline mutations of BRCA1 and BRCA2 are accountable for 5% to 10% of epithelial ovarian
cancer (Jazaeri, 2003). The history of ovarian cancer with BRCA1/BRCA2 mutations is more
likely linked to adenocarcinoma. Male carries of BRCA2 mutation also have a high risk of
cancer susceptibility. The cumulative lifetime risk for breast cancer among a male who carries
BRCA2 mutation is 7% to 8% (Evans et al., 2010). However, men without any mutation have a
0.1% lifetime risk. The NCCN panel recommends that individuals from a family with known
BRCA1/BRCA2 mutation should be considered at risk (Evans et al., 2010).
4.1.2 PTEN. PTEN is a tumor suppressor gene, and it regulates normal cell process,
including growth, adhesion, migration, invasion, and apoptosis (Yamada & Araki, 2001).
Approximately 80% of cancer patients carry a mutated PTEN gene if they meet NCCN clinical
criteria for Cowden syndrome. Women identified with Cowden syndrome have high risk of
benign fibrocystic breast diseases, and their lifetime risk of breast cancer has been estimated at
25% to 50% with an average age of 38 to 46 years at diagnosis.
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Cowden syndrome is considered as very rare disease, and it is underestimated because of
the difficulties associated with clinical diagnosis. Cowden syndrome is associated with the tumor
suppressor gene PTEN, and it exhibits the autosomal dominant inheritance pattern (Pilarski,
2009). PTEN gene mutation is also related with PTEN Hamartoma tumor syndromes (PHTS),
Bannayan Riley Ruvalcaba syndrome (BRRS), Proteus syndrome, Proteus-like syndromes,
Lhemitte-Duclos disease, and autism spectrum diseases (Eng, 2014; Pilarski, 2009; Pilarski,
Stephens, Noss, Fisher, & Prior, 2011). PTEN mutation is associated with breast cancer, thyroid
cancer, endometrial cancer, colorectal cancer, renal cancer, and melanoma. The calculated
lifetime risk of cancer is 85% for breast, 34% for renal, 35% for thyroid, 28% for endometrial,
9% for colorectal, and 6% for melanoma (Tan et al., 2012). Women with PHTS have higher risk
than men with PHTS. Women diagnosed with Cowden syndrome have high risk of developing
fibrocystic breast diseases which has breast cancer risk ranges from 25% to 50%. There are only
two cases reported in men with Cowden syndrome (Pilarski, 2009). Approximately 70% people
with the PTEN gene mutation are linked with multi-nodular goiter, follicular adenomas,
adenomatous nodules, and follicular adenomas. Classic features of Cowden syndrome include
mucocutaneous papillomatous papules, trichilemmomas, and palmoplantar keratosis. The study
shows that about 40% people with Cowden syndrome have gastrointestinal polyps
(hamartomatous, ganglioneuromas). The people who meet the criteria have a risk of carrying the
PTEN gene of 85% or higher (Gonzalez et al, 2009; Schaffer, Kamino, Witkiewicz, McNiff, &
Orlow, 2006). Early onset colorectal cancer is found in person with PTEN mutations. People
with BRRS variant have approximately a 60% risk of PTEN mutation. The people who meet
Cowden syndrome criteria will have about an 80% chance of carrying faulty a PTEN gene
(Gonzalez et al, 2009). While calculating Cowden syndrome risk, there are some major and
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minor features that should be considered. The major features include the personal history of
breast cancer, follicular thyroid cancer, endometrial cancer, macrocephaly, multiple
gastrointestinal hamartomas or ganglioneuromas, and certain mucocutaneous lesions (Eng, 2000;
Pilarski et al., 2009). A person who meets two or more major criteria with one macrocephaly
meets the criteria for Cowden syndrome. An individual who meets three or more major criteria is
at risk of PTEN mutation. A person with one major criterion and three minor criteria is also
considered a person at risk. The minor criteria include colon cancer, autism spectrum disorder,
esophageal glycogenic acanthosis, mental retardation, lipomas, thyroid cancer, gastrointestinal
hamartoma, and testicular lipomatosis (Eng, 2000; Pilarski et al., 2009). An individual who
meets four or more minor criteria can be considered at risk of Cowden syndrome. A first-degree
relative with one or more major criteria and two or minor criteria along with a relative diagnosed
with Cowden syndrome meets the threshold.
4.1.3 Tp53. Tumor protein Tp53 is another gene that has high penetration to cause breast
cancer. Breast cancer is common in women with Li-Fraumeni Syndrome (LFS). There are
different tumors associated with LFS syndrome (Gonzalez et al., 2009). The LFS tumor spectrum
includes soft-tissue sarcoma, osteosarcoma, pre-menopausal breast cancer, brain tumors,
adrenocortical carcinoma (ACC), leukemia, and lung Bronchoalveolar cancer (LFS tumor
spectrum). The lifetime risk of breast cancer in a woman with the Tp53 gene is 49% by the age
of 60. According to the clinical study, a patient with invasive breast cancer and a family history
of no core cancer has a 0% chance of having the p53 mutation. However, a person with breast
cancer under the age of 30 and with a family history of one or more core cancers in first- or
second-degree relative has a 100% chance of having the p53 mutation. Patients younger than 30
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with unilateral breast cancer and no cancer in first- or second-degree relative have a 7% chance
having the p53 mutation (Gonzalez et al., 2009).
Li-Fraumeni syndrome is a rare hereditary diseases associated with germline mutations of
Tp53. Only 1% of hereditary breast cancers are related with germline mutation of Tp53. It is
located on chromosome 17 and it is known as “guardian of genome.” Tp53 gene plays an
important role in cell cycle and apoptosis. An individual who meet Classic Li-Fraumeni
syndrome criteria has a 50% - 70% risk of Tp53 gene mutation. LFS is a high penetrant cancer
syndrome, and it is associated with soft-tissue sarcomas, osteosarcomas, acute leukemia, colon
cancer, premenopausal breast cancer, adrenal cortex cancer, and brain tumors. Sarcoma, breast
cancer, adrenocortical tumors, and brain tumors are known as core cancers of LFS syndrome, as
they are mostly related to Tp53 mutation. Studies show that HER-positive breast tumors are
highly associated with Tp53 mutation. Individuals with soft-tissue sarcomas, brain tumors, or
adrenocortical carcinomas at early ages will have a high lifetime risk of developing multiple
primary cancers. When compared with males, female breast cancer is more often related to LFS
syndrome. NCCN guidelines give different criteria to identify LFS syndrome. Classic LFS
syndrome criteria include individuals with known Tp53 mutation, individuals diagnosed with
sarcoma before the age of 45 years, a first-degree relative diagnosed with cancer before the age
of 45, and an additional first- or second-degree relative with the same cancer diagnosed at the
age of 45 or younger or with sarcoma at any age. Classic LFS has high prediction value (56%)
and specificity. Some other works have been done by different groups to make the LFS criteria
more accurate and predictive. Birch and colleagues have added more cancers to the LFS criteria.
Chompret and his colleagues added many criteria, including patients with multiple tumors, at
least two core tumor types diagnosed before the age of 36, and patients with adrenocortical
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carcinoma diagnosed at any age. The Chompret criteria has 20% to 35% prediction values, and
when it is added to classic LFS criteria, it improves the prediction value to 95%. Women who
identify breast cancer before the age 35 with or without family history of core cancers of LFS
syndrome can be considered at risk of Tp53 mutation. Studies show that women with breast
cancer before the age of 35 have a 3% to 8% risk of Tp53 mutation. A member from a family
with known deleterious Tp53 mutation is always at risk even without any symptoms of cancer.
4.2 Inheritance Patterns of BRCA1, BRCA2, Tp53 and PTEN Genes
Humans have twenty-three pairs of chromosomes. The first twenty-two are called
AUTOSOMES and the twenty-third pair is the SEX CHROMOSOMES (the pair of
chromosomes that determines the gender of the offspring) (NLM, 2015). Mutated genes are
inherited from biological parents in specific ways. Autosomal dominant inheritance is one of the
basic patterns of inheritance. Autosomal dominant inheritance means that the gene carrying a
mutation is located on one of the autosomes (chromosome pairs 1 through 22). This means that
males and females are equally likely to inherit the mutation. In autosomal dominant mutation,
just one of the two copies of a particular gene is enough for a person to have a trait, such as an
increased risk of developing cancer (Chapman, 2007). Autosomal recessive inheritance means
that the gene carrying the mutation is located on one of the autosomes (chromosome pairs 1
through 22). In autosomal recessive inheritance, both copies of the gene must have a mutation in
order to make a person have the trait. A person who has only one recessive gene mutation is said
to be a "carrier" of the trait or disease, but he/she does not have any health problems from
carrying this one mutated gene (Williams, 1997).
Genetic conditions are caused by mutations in single genes and can be inherited in
different ways. Single gene inheritance is called Mendelian inheritance, and there are four
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different types of Mendelian inheritance patterns: 1) autosomal dominant, 2) autosomal
recessive, 3) X-linked recessive, and 4) X-linked dominant (National Library of Medicine,
2015).
4.2.1 Autosomal dominant inheritance. Autosomal dominant inheritance means that the
gene carrying a mutation is located on one of the autosomes (chromosome pairs 1 through 22). In
autosomal dominant inheritance, only one copy of the faulty gene is sufficient to make the
individual at the risk of the disease. Autosomal dominant disorders are likely to occur in each
generation of an affected family.
When a parent has a dominant gene mutation, there is a 50% chance that any child he/she
has will also inherit the mutation. There are four possible combinations in the children. Two of
the four, or 50%, have inherited the mutation. The other 50% have not inherited the mutation.
These four combinations are possible every time a pregnancy occurs between these two
individuals. The gender of the children (whether they are sons or daughters) does not matter. The
chance is fifty-fifty for each pregnancy. BRCA1, BRCA2, PTEN and Tp53 genes exhibit the
autosomal dominant inheritance pattern.
4.2.2 Autosomal recessive inheritance. In each cell, two mutated copies of the gene
should be present to make the person at risk of disease. "Recessive" means that both copies of
the faulty gene should be inherited to make the person susceptible. A person who has only one
recessive gene mutation is said to be a "carrier" for the trait or disease, but he/she does not have
any health problems from carrying this one mutation. Most people do not know they carry a
recessive gene mutation for a disease until they have a child with the disease. Once parents have
had a child with a recessive disease, there is a one out of four, or 25%, chance with each
subsequent pregnancy for another child to be born with the same disorder. This means that there
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is a three out of four, or 75%, chance for another child to not have the disease (National Library
of Medicine, 2015).
4.2.3 X-linked dominant inheritance. X-linked dominant conditions are affected by
mutations in genes on the X chromosome. Females are more commonly affected than males, and
passing on an X-linked dominant disorder has a different outcome for men and women. Families
with X-linked dominant diseases have frequently affected both males and females in each
generation. In X-linked inheritance, the father cannot pass the faulty gene to their sons (NLM,
2015).
4.2.4 X-linked recessive inheritance. These disorders are due to the mutations in genes
on the X chromosome. Males are more often affected than females. X-linked recessive disorders
are frequently found in males but rarely affect females.
The next section will explain how the inheritance pattern is used for this software tool.
The BRCA1/BRCA2, PTEN, and Tp53 genes exhibit autosomal dominant inheritance pattern.
The mutated gene can be inherited by the next generation in different ways, and it depends on the
gene that is involved with the disease. Consider a mother who is the carrier of the abnormal gene
“a” and the father who is carrying the normal gene “A”, as shown in Figure 3. In hereditary
breast cancer, the gene passes to the next generation through an autosomal dominant inheritance
pattern. Every child inherits two copies from their parents, one from their mother and one from
the father (National Center for Biotechnology Information [NCBI], 2009; HHS, 2013). When a
parent has a dominant gene mutation, there is a 50% chance that any child from each pregnancy
will inherit the mutation. The BRCA1, BRCA2, Tp53, and PTEN genes exhibit the autosomal
inheritance pattern.
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Figure 3. Autosomal dominant inheritance pattern.
A person with autosomal dominant inherited diseases will have four different possibilities
with each pregnancy. Two out of the four, or 50%, can inherit the mutated genes (aA, aA). The
other 50% do not inherit the mutated genes (AA, AA). These four combinations are possible
every time a pregnancy occurs. The gender of the children does not matter.
4.3 How the Traits are Passing Down to the Generations?
Most cancers are non-hereditary, and hereditary cancers are commonly caused by genetic
defect. There are two main categories of mutation based on the type of cell that the genetic
change occurs in. Mutations that are passed from parents through the egg or sperm are known are
inherited mutations. Somatic mutations can happen in the lifetime of any person. They are not
inherited from their parents and it will not pass to the next generations.
Two main types of genes that play a role in cancer are proto-oncogenes and tumor
suppressor genes. Tumor suppressor genes control cell division and repair DNA mistakes. When
tumor suppressor genes don't work properly, cells can grow out of control, which can lead to
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cancer. Many different tumor suppressor genes have been found, including TP53 (p53), BRCA1,
BRCA2, APC, and RB1. Proto-oncogenes speed up the cell division and in any mutation can
cause uncontrollable growth of the cells. The mutated proto-oncogenes are called oncogenes.
When this happens, the cells grow out of control, which can lead to cancer.
The mutated gene can be inherited to the next generation in different ways, and it
depends on the gene that involved with the disease. Genes are found in pairs. Each parent
contributes one copy of the gene to their child. These gene copies can be inherited from parents
in different ways, which are called inheritance patterns.
For example, some of the hereditary disease shows autosomal recessive inheritance. That
means two copies of the abnormal genes must be present in order for the disease or trait to
develop. Most people do not know that they carry a recessive gene mutation for a disease until
they have a child with the disease. Once the mother has conceived a child, there is 25% chance
of getting a normal child without the mutated gene. There will be a 25% of chance a child born
with the disease. This means that there is a two out of four, or 50%, chance of getting a child
who carries the mutated gene and may not show any symptoms of the disease in his or her
lifetime.
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CHAPTER 5

Prediction of Hereditary Breast Cancer
The capabilities of today’s digital world make innovative progress in health care. Doctors
take advantage of fully functional and exchangeable electronic health records to provide better
treatment and care. Health records that are stored in an electronic format deliver high accuracy in
diagnoses and health outcomes. Nowadays, people use the Internet and medical websites to get
more health information about diseases. Cancer is predictable in current or future generations
based on the information gathered from family history tools and genetic and medical
information. Collecting data from close relatives may be sufficient in determining the risk.
However, risk prediction will be limited if the families are small. Predictions of diseases like
breast, ovarian, colorectal, and prostate cancers have high degrees of accuracy if they have been
developed based on family history (Santaguida et al., 2007). Identifying repeated diseases and
associated genes would help to forecast the disease in the future generation (offspring). As we
are concentrating on breast cancer, the next section will explain how a family history will be
useful in predicting breast cancer in any individual or their next offspring. The aim of this
research is to develop a software tool to predict hereditary breast cancer. We combine the
medical, genetic, and family health history reports to create the program.
5.1 Flowchart to Predict the Hereditary Breast Cancer Risk
There are different models and software programs that have been developed to predict the
risk of breast cancer (Evans & Howell, 2007). However, these tools do not consider other genes
such as TP53 and PTEN that contribute a high risk for breast cancer. In this computer program,
we have combined BRCA1/BRCA2, TP53, and PTEN gene risks. We are using National
Comprehensive Cancer Network guidelines to predict BRCA1, BRCA2, TP53, and PTEN
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mutation risk. According NCCN members Daly et al, the guidelines for breast and ovarian
cancer are focusing on assessment of mutations in the genes BRCA1, BRCA2, TP53, and PTEN,
and recommended approaches to genetic testing and management strategies.
The National Comprehensive Cancer Network (NCCN) is an association of twenty-five
global leading cancer centers. The association develops guidelines for most cancers and is
updated by forty-seven individual panels, including over 950 clinicians and oncology researchers
from the twenty-five institutions that are members of the NCCN. The panel members include
clinicians and researchers, and they have several academic disciplines. According to NCCN
guidelines (Daly et al., 2014), “It should be emphasized that these guidelines were not developed
as a substitute for professional genetic counseling. Rather they are intended to serve as a resource
for healthcare providers to identify individuals who may benefit from cancer risk assessment and
genetic counselling, to provide genetic counselors with an updated tool for the assessment of
individual breast cancer and ovarian cancer risk and to guide decisions related to genetic testing,
and to facilitate a multidisciplinary approach in the management of individuals at increased risk
of hereditary breast and ovarian cancer. Although cancers other than breast and ovarian cancers
are associated with these hereditary syndromes, the main focus of this NCCN Guidelines is on
the management of breast and ovarian cancer risk in these individuals” (Daly et al., 2014).
Moreover, new guidelines go through annual reviews, and it will be circulated among
multidisciplinary researchers for comments at each NCCN branches.
The flowcharts have been developed based on NCCN guidelines, and the analysis has
been divided into three sessions: 1) Hereditary breast/ovarian cancer syndrome analysis 2) LiFraumeni syndrome analysis and 3) Cowden syndrome analysis. These three syndromes are
related to germline mutation of BRCA1/BRCA2, TP53, and PTEN genes that have high impact
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on hereditary breast cancer diagnoses. The below figures give details about the logical flow of
the program. In this program, we have used the latest version of the guidelines (Daly et al.,
2014).
5.1.1 Checking BRCA1/BRCA2 mutation.

Figure 4. BRCA1/BRCA2 personal history analysis.
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Figure 5. BRCA1/BRCA2 personal history analysis (cont.).
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Figure 6. BRCA1/BRCA2 family history analysis.
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Figure 7. BRCA1/BRCA2 family history analysis (cont.).
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The figure 4 and figure 5 shows the procedures of personal history analysis of BRCA1 or
BRCA2 mutation risk. After collecting the information about already known or diagnosed
mutation of BRCA1/BRCA2 gene, it checks the personal history of breast cancer.
In order to check the personal history of breast cancer, the flowchart has been divided
into four groups based on different age category. The risk criteria will be met if the person is
under the age category ‘a’ (age <=45), and there are no additional criteria needed to satisfy the
‘at risk’ condition. The criteria will be met, if the person is under or at the age of 50, and if
she/he has any additional primary breast cancer or more than one close blood relatives with
breast cancer. The person will be at risk if she/or he has an unknown family history. If the age
category is 60 or under, the result will be stored if the person is identified with triple negative
breast cancer. For ‘at any age’ category, and the criteria will be met if more than one close blood
relatives with breast cancer at 50 or younger age, or more than two close blood relatives with
breast cancer at any age, or more than one close blood relatives with male breast cancer, or more
than close blood relatives with pancreatic or prostate cancer. The result will be stored, if the
person belongs to Ashkenazi Jewish Ancestry, and if the person has a personal history or family
history of breast or prostate cancer.
After that, the result will be stored if the person has an epithelial ovarian cancer history.
In addition, the flowchart checks the personal history of male breast cancer. Next, it checks the
personal history of pancreatic or prostate cancer.
After checking the personal history of pancreatic or prostate cancer history, the family
history of breast, ovarian, pancreatic and prostate cancers will be checked. If there are more than
two relatives from the same side of the family is affected with any of these cancers, the result
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will be stored as ‘at risk’. For pancreatic cancer, if the person belongs to Ashkenazi Ancestry,
then only one additional affected relative is needed to meet the criteria.
The figures 6 and 7 show the procedures of family history analysis. The same steps that
has been used for personal history analysis will be used to check the family history (only for
first- or second-degree relatives) analysis.
After collecting the information of already known or diagnosed gene mutation, the
relative’s family history will be checked. For that, the flowchart collects the information about
first- or second-degree relative’s personal history of breast cancer. Checking personal history of
breast cancer has divided into four based on the age group. The information will be collected
separately for different age category.
After that, the flowchart checks if the person has a history of epithelial ovarian cancer.
Next, it will check the presence of pancreatic and prostate cancer and also checks the male breast
cancer history. If the person has a first- or second-degree relative with these cancers, the result
will be stored and enter into next section.
To check a third-degree relative’s family history, a different method has been followed. If
a third-degree relative is identified with breast or ovarian cancer, the flowchart checks the
number of other relatives who have identified with breast or ovarian cancer in the same side of
the family. If there are more than two people identified with breast or ovarian cancer (one at least
before the age of 50), the result will be stored as ‘at risk’.
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5.1.2 Checking Tp53 mutation.

Figure 8. Tp53 mutation analysis.
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The figure 8 shows the procedures to check the Tp53 mutation. To begin with, the
information will be collected if the person is already identified with Tp53 mutation.
In the next step, it checks whether the person meets classic-Li-Fraumeni syndrome
criteria or not. In order to check the classic Li-Fraumeni syndrome criteria, the flowchart checks
if the person is identified with a sarcoma before the age of 45. If the person is diagnosed with
sarcoma, first- or second relative’s history of cancer before the age of 50 will be checked. If the
first-, or second-degree relative is identified with cancer, it checks the additional relative’s
history of cancer. The result will be stored as ‘at risk’ if all three criteria has been met.
Next, the procedure enters into Chompret criteria section. Checking Chompret criteria
starts from identifying individual with a tumor that belongs to LFS tumor spectrum before the
age of 46. LFS tumor spectrum includes sarcoma, brain tumor, breast cancer, leukemia,
adrenocortical carcinoma and lung Broncho alveolar cancer. Next, the relative’s history of LFS
tumors (include breast primaries) will be checked if the individual is identified with LFS tumors.
After that, it checks whether the individual is diagnosed with multiple tumors, and two of them
belongs to LFS spectrum or not. If yes, the result will be stored as ‘at risk’. In the final step, the
flowchart checks if the individual is diagnosed with adrenocortical carcinoma or Choroid plexus
carcinoma.
In the next step, the flowchart checks if the person is diagnosed with breast cancer before
or at the age of 35-year-old. If the person meets the criteria, he/she is at risk of both Tp53 and
BRCA gene mutation. The result will be collected if the condition is satisfied, and enter into
PTEN mutation analysis.

56
5.1.3 Checking PTEN mutation.

Figure 9. PTEN analysis.
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Figure 10. PTEN analysis (cont.).
The figures 9 and 10 explain the procedures involved in PTEN mutation analysis. First of
all, the flowchart checks if the person is already known or diagnosed PTEN gene mutation, and
then the result will be collected. In next step, it checks if the individual is meeting clinical
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diagnostic criteria for CS/PHTS and the information will be collected if the person has met the
criteria. After that, it checks the personal history of Bannayan_Riley Ruvalcaba syndrome, and
the information will be stored if it is identified. Next, the flowchart enter into checking of
personal history of Adult Lhermitte Duclos disease, and the result will be stored if the person
has/had a history of the disease. Then, it checks the personal history of autism spectrum disorder
and macrocephaly condition. After that, it checks two or more biopsy-proven trichilemmomas.
After collecting the result, it checks whether the person is meeting three major clinical diagnostic
criteria without macrocephaly. Next, the flowchart enters into identification of two or more
major criteria with macrocephaly or it checks whether the person has met one major criterion and
more than three minor criteria. In the next step, the flowchart checks whether the individual
meets more than four minor criteria or not. After that, the flowchart checks if any of the
individual’s family member meets one major criterion and two or more minor criteria. The result
will be stored if the criteria have been met. In final section, the result stored from different
sections will be combined and displays the result based on the different combination of the
result. The final output gives a separate report based on the three sections.
5.2 Proposed Design
The proposed block diagram of the program is shown in Figure 4. We have considered all
the clinical possibilities, including inheritance pattern, family history assessments, and medical
reports to generate the program.
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Figure 11. Proposed design.
As described earlier, this program has three sections (BRCA1/BRCA2 checking, Tp53
checking and PTEN mutation checking). As shown in the above figure, the program analyzes
personal history, family history and already known mutation condition. The program checks
individual known mutation history, personal history, and family history for BRCA1/BRCA2,
Tp53 and PTEN gene mutation. The result of each section will be stored separately, whenever
the NCCN criteria are met. The program combines different section’s result and displays the
result based on the analysis. The result will contain the risk of passing mutation risk or getting
cancer in next generation. The family history includes, first, second and third-degree relatives
health history.
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Figure 12. A pedigree chart.
We have considered family history that includes first-, second-, and third-degree
relatives. The above figure 6 gives a detailed picture of first-, second-, and third-degree relatives.
First-degree relatives include parents, siblings, and children. Second-degree relatives include
grandparents, aunts, uncles, nieces, nephews, grandchildren, and half-siblings. Third-degree
relatives include great-grandparents, great-aunts, great-uncles, great-grandchildren, and first
cousins (Daly et al., 2014). The tool combines the personal history, family history, and known
mutation history to detect the presence of faulty genes. In the output, the tool combines all the
results from different sections and displays the results.
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5.3 Software Tool to Predict Hereditary Breast Cancer in Current and Future Generation
This software program was developed with JavaScript, HTML, and CSS.

Figure 13. Image of the software program.
Based on the guidelines, the program analysis is divided into three sessions: 1) Hereditary
breast/ovarian cancer syndrome analysis, 2) Li-Fraumeni syndrome analysis, and 3) Cowden
syndrome analysis.
5.3.1 Hereditary breast and ovarian cancer syndrome analysis. As the first step, the
program checks the breast and ovarian cancer syndrome (BRCA1/BRCA2 mutation). This part
of the program would check different criteria that are defined by NCCN to detect the presence of
BRCA1/BRCA2 genes. Based on the NCCN guidelines, individuals from a family with known
BRCA1 or BRCA2 mutation should be considered for testing. If the individual is not from a
known gene mutation, the risk can check based on the testing criteria discussed below. Close
relatives include first-, second- and third-degree relatives from the same side (paternal and
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maternal side) of the family. If the individual has less than two first- or second-degree relatives
can be considered as limited family history. The analysis has been divided into three sections: 1)
an individual with an already known or diagnosed BRCA1/BRCA2 mutation, 2) checking
personal history of different types of cancers, such as breast cancer, epithelial ovarian cancer,
male breast cancer, pancreatic or prostate cancer, and Ashkenazi ancestry, and 3) checking
family history of the person. The program checks personal and family histories to detect the
presence of mutation. The tool also checks the presence of different hereditary cancers such as
epithelial ovarian cancer, prostate cancer, pancreatic cancer, and male breast cancer, and it also
checks ancestry (e.g., Ashkenazi Ancestry). The result will be stored if any criteria are met.
5.3.1.1 Person with known mutation. This part will check whether the individual is
already diagnosed with BRCA mutations or if he or she has a known personal/family history of
BRCA1/BRCA2 mutation. If the person has a genetic report or medical report that identify the
mutation of BRCA1/BRCA2 gene, she/he will be considered as at risk of developing breast
cancer. The lifetime risk vary from 41% to 85%. If there is a history of already known
BRCA1/BRCA2 mutation, the tool will consider the person as having met the NCCN criteria and
will store the result as positive.
5.3.1.2 Personal history. In the next section, the program analyzes the personal history
of cancers that related with BRCA1 and BRCA2 mutation. Checking personal history has been
divided into four subsections: a) personal history of breast cancer, b) epithelial ovarian cancer, c)
male breast cancer and d) pancreatic or prostate cancer.
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Figure 14. Personal history-BRCA1/BRCA2 analysis.
5.3.1.2.1 Personal history of breast cancer. The personal history of breast cancer has
been divided into four different age groups: ages 45 and less, age less than or equal to 50, age
less than or equal to 60, and diagnosed at any age. The tool considers the result positive (at risk)
if any individual with a personal history of breast cancer meets any of the following criteria.


Diagnosed at the age of 45 or less: Hereditary breast cancers are likely to appear during
early stages of life. Identifying breast cancer before or at the age 45 is an indication of
inherited gene mutation.



Diagnosed at the age of 50 or less along with two breast primaries, one or more close
relative with breast cancer at any age, or unknown family history. Primary breast cancer
means that the breast cancer is not yet attacked other parts of the body. Women diagnosed
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with a primary breast cancer is at higher risk of developing a second primary cancer in
another breast.


Diagnosed at the age of 60 or less with triple-negative breast cancer. Triple-negative
breast cancer is a term that use in pathology. In pathology reports the negative results
mean that the cancer is not associated with HER2 (HER2-), estrogen receptors (ER-), and
progesterone receptors (PR-).



Diagnosed at any age with any of the following:


One or more close relatives with breast cancer diagnosed at the age of 50
years or younger,



A relative with epithelial cancer at any age,



Two or more relatives with pancreatic cancer or prostate cancer,



A close relative with male breast cancer,



Ashkenazi ancestry.

Ashkenazi Jewish people are originally from Central or Eastern Europe. They were
geographically and genetically isolated people for centuries. Therefore, faulty genes might have
been passed down through generations and as a result, put them more at risk. The lifetime risk of
getting breast cancer is 90% for any person who belongs to Ashkenazi Jewish ancestry with
mutated gene of BRCA. According to NCCN guidelines, if the patient is with personal history of
breast cancer and with an Ashkenazi Jewish ancestry, no additional family history is needed to
meet the criteria (Daly et al., 2014).
5.3.1.2.2 Personal history of epithelial ovarian cancer. Germline mutations of
BRCA1/BRCA2 genes are related to high risk of epithelial ovarian cancer (5% to 10%). A
person diagnosed with epithelial cancer at any age will be at risk of hereditary breast cancer.
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5.3.1.2.3 Personal history of male breast cancer. Personal history of male breast cancer
can be considered a potential factor related to hereditary breast cancer. Men with breast cancer
are more susceptible to BRCA2 gene mutation than BRCA1 mutation. The lifetime risk of breast
cancer with BRCA2 gene is 6% by age of 70, and it is only 1% with the BRCA1 gene.
5.3.1.2.4 Personal history of pancreatic or prostate cancer. Mutation in BRCA1 or
BRCA2 contributes high risk of pancreatic and prostate cancer. Men with BRCA1 or BRCA2
mutations have higher risk of developing prostate cancer. Both men and women with BRCA1 or
BRCA2 mutations have higher risk of pancreatic cancer (NCI, 2015). Especially, BRCA2
mutation exhibits higher risk than BRCA1 in prostate cancer with Gleason score greater than
eight. Both genes are also associated with high risk of developing pancreatic cancer. As a result,
the result will be “at risk” if the person has a personal history of prostate cancer or pancreatic
cancer at any age, and has two or more close relatives with breast, ovarian, pancreatic, or
prostate cancer. For pancreatic cancer, if the person belongs to Ashkenazi Jewish ancestry, only
one additional affected relative is sufficient to make the person at risk (Daly et al., 2014
The result of the personal history analysis will be stored and will continue to check
family history. The table below contains different test cases that were created for this section.
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Table 3

Do you have ever
diagnosed
with
epithelial ovarian
cancer?

Do you
have ever
diagnosed
with male
breast
cancer?

Personal
history of
prostate
cancer
with any of
the
following:

Belongs to
Ashkenazi
Jewish
family

Personal
history of
pancreatic
cancer at any
age with any
of the
following:

Expected result

at any age with

Personal history of breast cancer and
belongs to:

<=60 tripe –ve

Have you
ever
diagnosed
with breast
cancer?

<= 50 old

Do have any
family member
with known
hereditary breast
cancer
(BRCA1/BRCA2
mutation)?

<=45 old

Test cases

Test Cases for Personal History-BRCA1/BRCA2 Analysis

P1

Yes

No

At risk

P2

No

Yes

P3

No

yes

additional
primary

At risk

P3

No

Yes

>=1
relatives
with BC

At risk

P4

No

Yes

Unknown
family
history

At risk

P5

No

Yes

P6

No

Yes



At risk



At risk
>=1
close
relatives with
BC
diagnosed at
the age of
<=50 old

At risk
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P7

No

Yes

P8

No

Yes

P9

No

Yes

P10

No

Yes

P11

No

Yes

P12

No

Yes

P13

No

Yes

P14

No

Yes

P15

No

Yes

P16

No

Yes

>=2 relatives
with breast
cancer
>=1
close
relatives with
epithelial OC
>=2 relatives
with
pancreatic
cancer
>=2 relatives
with prostate
cancer
close relative
with
male
breast cancer

At risk

At risk

At risk

At risk

At risk


At risk


At risk
>=2
relatives
with breast
cancer
>=2
relatives
with
pancreatic
cancer
>=2
relatives
with
prostate
cancer

At risk

At risk

At risk
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P17

No

Yes

>=2 close
relatives
with
epithelial
OC
One more
additional
relative

At risk

P18

No

Yes

P19

No

Yes

P20

No

Yes

>=2 relatives
with
breast
cancer

At risk

P21

No

Yes

At risk

P22

No

Yes

>=2 relatives
with
pancreatic
cancer
>=2 relatives
with prostate
cancer

P23

No

Yes

>=2
close
relatives with
epithelial OC

At risk



At risk



At risk

At risk

BC stands for breast cancer, OC stands for epithelial ovarian cancer, PC-pancreatic cancer, Prc-prostate cancer, MBC- Male
breast cancer. All of these test cases are for people who are ‘at risk’, and any other conditions or combinations would give the result as
‘not at risk ‘.
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5.3.1.3 Family history. In the next section, the program checks the family history. The
tool examines the family history and determines the risk based on the frequency of cancer
appearing in first-, second-, or third-degree relatives. The output will be stored based on the
analysis of the family history. This section has been separated into two subsections to qualify the
different conditions for the diagnosis.
5.3.1.3.1 First- or second-degree relatives. First or second-degree relatives who satisfy
the conditions. The conditions are same as the criteria used for checking personal history, and it
has been discussed earlier in the personal history section.
5.3.1.3.2 Third-degree relatives. Third-degree relatives with breast cancer and or ovarian
cancer with two or more close blood relative with breast cancer (one at least before the age of
50) or ovarian cancer.

Figure 15. Family history-BRCA1/BRCA analysis.
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Table 4

1

Yes

No

2

No

Yes

3

No

Yes

4

No

Yes

5

No

Yes

6

No

Yes

7

No

Yes

8

No

Yes

<=
45

Family History

<=50

<=60

any age

Third degree relative with

Ashkenazi

the age at diagnosed

Epithelial
OC

1st/2nd degree
relatives with
breast cancer

Test cases

Known mutation

Test Cases for Family History –BRCA1/BRCA2 Analysis

Pancreatic

Prostate

Breast
cancer

Ovarian
cancer

Expected
Result
At risk



Additional
primary

At risk

>=1
relatives
with BC
Unknown
family
history

At risk

At risk
Triple ve BC

At risk
>=1 close
relatives
with BC
diagnosed
at the age
of <=50 old
>=2
relatives
with breast
cancer
>=1 close
relatives
with
epithelial
OC

At risk

At risk

At risk
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9

No

Yes

10

No

Yes

11

No

Yes

12

No

Yes

13

No

Yes

14

No

Yes

15

No

Yes

16

No

Yes

17

No

Yes

18

No

Yes

>=2
relatives
with
pancreatic
cancer
>=2
relatives
with
prostate
cancer
close
relative
with male
breast
cancer

At risk

At risk

At risk
At risk
At risk
>=2 relatives
with breast
cancer
>=2 relatives
with
pancreatic
cancer
>=2 relatives
with prostate
cancer
>=2 close
relatives with
epithelial OC
One more
additional
relative

At risk

At risk

At risk

At risk


At risk
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19

No

Yes

20

No

Yes

21

No

Yes

22

No

Yes

23

No

Yes

24

25

No

No

Yes

Yes


>=2 relatives
with breast
cancer
>=2 relatives
with
pancreatic
cancer
>=2 relatives
with prostate
cancer
>=2 close
relatives
with
epithelial
OC

At risk

At risk

At risk

At risk

At risk
>=2 relatives
with ovarian
cancer

At risk
>=2
relatives
with breast
cancer

At risk

The above test case are for family history section. The test cases checks different scenarios for different age groups. In all of
the above conditions, the expected output is ‘at risk’. The result will be stored as the program enters the next section.
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The risk of breast cancer increases if the person has close blood relatives with a history of
breast cancer. The risk increases as the number of affected relatives increases and also varies
with people’s race and ethnicity. The next section analyzes Li-Fraumeni syndrome (Tp53).
5.3.2 Li-Fraumeni syndrome analysis. At this stage, the software tool checks the
presence of Li-Fraumeni syndrome. Breast cancer is common in women with Li-Fraumeni
Syndrome (LFS). This syndrome is associated with germline mutation of Tp53 gene. The related
tumors and cancers associated with Li-Fraumeni Syndrome are soft-tissue sarcomas,
osteosarcomas, premenopausal breast cancer, adrenal cortex, colon cancer, acute leukemia, and
brain tumors. The core cancers related with LFS syndrome are sarcoma, adrenocortical
carcinoma, breast cancer and brain tumors. Chompret criteria and Classic Li-Fraumeni
Syndrome criteria are the two different criteria that have been widely used to check the Tp53
mutation. The flowchart to check Tp53 mutation (Li-Fraumeni syndrome) is given in flowchart
section b. The program can be divided into four parts based on different checking criteria. In this
section, the software tool checks four different conditions: a) an individual with known
mutations, b) classic Li-Fraumeni syndrome criteria, c) Chompret criteria, and d) early age onset
criteria. The result will not be stored if the conditions are not met. However, in either condition
(criteria met or not), the program will enter into the next section. The analysis has been done as
follows:
5.3.2.1 Individual from a family with known mutation. In this part, the program checks
if the individual is from a family that is already known to have or is diagnosed with the mutation
of Tp53. If the individual has an already identified the mutation of Tp53, then the program would
consider the person at risk and enter into the next section after storing the result. According to
NCCN guidelines, people who are already diagnosed with Tp53 gene mutations are at risk of
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hereditary breast cancer. People who carry the Tp53 mutated gene have a 21% to 49% risk of
developing breast cancer by the age of 30, and the lifetime cancer risk is 68% to 93%.
5.3.2.2 Checking classic Li-Fraumeni Syndrome criteria. To meet NCCN criteria for
classic Li-Fraumeni Syndrome Criteria, the person should satisfy all three conditions.


Individual is diagnosed with sarcoma ( cancer related to connective tissues) before the
age of 45 years; and



Individual has a first-degree relative with cancer, and it was diagnosed before the age of
45; and



Individual has one or more first- or second-degree relatives with cancer diagnosed before
the age of 45 or with a sarcoma at any age.
5.3.2.3 Checking Chompret criteria. This part the program analyzes three conditions

given below. If any of the conditions are met, the output will be stored and the program will exit
from the section.


Individual with a tumor from LFS tumor spectrum (soft-tissue sarcoma, osteosarcoma (
cancer develops in bone), brain tumor, breast cancer, adrenocortical carcinoma, leukemia,
lung Broncho alveolar cancer) before 46 years of age, and one or more first- or seconddegree relatives with cancers that included in the LFS spectrum before the age of 56
years or with multiple primaries at any age; or



Individual with multiple tumors and two of them belonging to LFS spectrum and
diagnosed before the age of 46 years; or



If the individual was diagnosed with adrenocortical carcinoma (a cancer that begin at the
outer layer of the adrenal gland) or choroid plexus carcinoma (tumor arises from brain
tissues) at any age of onset, regardless of the family history.
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5.3.2.4 Early-age-onset criteria. An individual diagnosed with breast cancer before the
age of 35 years can be considered as a person at risk of Tp53 mutation. A person with breast
cancer under the age of 30 and with a family history of one or more core cancers in first- or
second-degree relative has a 100% chance of having the p53 mutation.

Figure 16. Tp53 analysis.
The above figure is a screenshot from the Tp53 mutation analysis. This section includes
ten questionnaires to check the risk of mutated gene. Based on the user’s selections the program
will check the risk of Tp53 mutation. The accuracy of Chompret criteria alone is 92%. However,
the combination of classic Li-Fraumeni syndrome criteria and Chompret criteria exhibits 99%
accuracy (Gonzalez et al., 2009).
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Table 5

Test
cases

Indivi
dual
from a
known
mutati
on?

Have you
ever
diagnosed
with
sarcoma
before the
age of 45?

Do you have
a 1st degree
relative
diagnosed
with cancer
before the age
of 45?

P1







P2



P3



P4

Do you have
a 1st or 2nd
degree
relative with a
cancer before
age 45 or
sarcoma at
any age?

Please select if
you have
diagnosed with
any (before the
age of 46):

Please select if
you have 1st or
2nd degree
relative
diagnosed with
any (before the
age of 56):

Do you have
diagnosed with
any of the
condition in the
list before the age
of 46?

Have you ever
diagnosed
with:

Breast
cancer
diagnosed
before the
age of 35?

Expected Result *

Test Cases for Tp53 Analysis

At risk
Not at risk





At risk
Soft tissue
sarcoma

P5

Brain tumor

At risk

Brain tumor

Not at risk

P6

Osteosarcoma

Leukemia

At risk

P7

Breast cancer

Soft tissue
sarcoma

At risk

P8

Adrenocortical
carcinoma

Leukemia

At risk

P9

Leukemia

Soft tissue
sarcoma

At risk

P10

Lung Broncho
alveolar cancer

Adreno cortical
carcinoma

At risk

P11

Leukemia

Soft Tissue
Sarcoma, Brain
tumor

At risk
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P12

Multiple breast
tumors

Not at risk

P13

Adrenocortical
carcinoma

At risk

P14

Choroid plexus
carcinoma

At risk


P15
P16

Leukemia

At risk
Not at risk

P17

Soft tissue
sarcoma

Not at risk

P18

Osteosarcoma

Not at risk

P19

Breast cancer

Not at risk

P20

Adrenocortical
carcinoma

Not at risk

P21

Leukemia

Not at risk

P22

Lung Broncho
alveolar cancer

Not at risk

The above table includes different test cases followed for Tp53 analysis section.
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5.3.3 Cowden syndrome analysis. In this part, the program checks PTEN (Cowden
syndrome) mutation. Cowden syndrome is related to mutations in the PTEN gene. In order to
calculate the risk, the flowchart will check four criteria. There are some major and minor criteria
that should satisfy the person to be at risk.
Major criteria include:


Breast cancer



Endometrial cancer – Cancer begins in the inner layer of the uterus.



Follicular thyroid cancer



Multiple GI hamartomas or ganglioneuromas – Cancer starts in the nerve cells



Macrocephaly (58 cm in adult women, 60 cm in adult men) – A condition in which the
head circumference is larger than normal.



Macular pigmentation of glans penis



Mucocutaneous lesions with any of the following:
o One biopsy-proven trichilemmoma (tumor begins in the hair follicle)
o Multiple palmoplantar keratosis (abnormal thickening of palms and soles)
o Multifocal or extensive oral mucosal papillomatosis ( a skin surface elevation)
o Multiple cutaneous facial papules ( a skin disorder)

Minor criteria include:


Autism spectrum disorder



Colon cancer



Three or more esophageal glycogenic acanthoses (white plaque found in esophagus )



Lipomas – A tumor which is composed of body fat.



Mental retardation
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Papillary or Follicular variant of papillary thyroid cancer



Thyroid structural lesions



Renal cell carcinoma – A type of kidney cancer



Single GI hamartoma or ganglioneuroma



Testicular lipomatosis



Vascular anomalies

Figure 17. PTEN analysis.
The above figure is a screenshot of PTEN analysis section. As shown in the figure, the
program checks individual known mutation history, personal history and family history. The
major and minor criteria dropdowns include different clinical criteria for PTEN gene testing. The
program determines the risk of mutation based on the selections that have been made by the user.
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Table 6
Test Cases of PTEN Analysis
Test
cases

P1
P2

P3

P4

P5

P6
P7

P8

P9

Are you
already
diagnosed or
known
mutation in
PTEN gene


Individual
with a personal
history of:

Do you have any close
relative with:

Major Criteria:

Minor Criteria:

Expected Result

At risk
BannayanRileyRuvalcaba
syndrome
Adult
LhermitteDucolos
diseases
Autism
spectrum
disorder and
macrocepahly
Two or more
biopsy-proven
trichilemmoas

At risk

At risk

At risk

At risk

Breast cancer
Endometrial cancer
Follicular thyroid cancer
Multiple GI hamartomas or
gangalloneuromas
Macrocephaly
Macular pigmentation of
glans penis
Mucocutaneous lesions and
One biopsy-proven
trichilemmoma

At risk
At risk

At risk

At risk
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P10

P12

Mucocutaneous lesions and
Multiple palmoplantar
keratosis
Mucocutaneous lesions and
Multiple cutaneous facial
papules
Breast cancer

P13

Endometrial cancer

P14

Follicular thyroid cancer

P11

P15

P16

P17

Breast cancer
Endometrial
cancer
Multiple GI
hamartomas or
gangalioneuromas
Macrocephaly

The above table-6 include different test criteria for PTEN gene mutations.

At risk

At risk

Autism spectrum disorder,
Colon cancer,
Three or more esophageal glycogenic
acanthoses,
Lipomas
Lipomas,
Mental retardation,
Colon cancer
Lipomas,
Mental retardation,
Colon cancer
Autism spectrum disorder,
Colon cancer, Lipomas,
Mental retardation,
Papillary or Follicular variant of papillary
thyroid cancer

At risk

At risk

At risk

At risk

At risk

At risk
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The program has four sections: 1) individual from a family with an already known
mutation, 2) individual meeting clinical diagnostic criteria, 3) individual with personal history
and other NCCN criteria 4) individual with a close blood relative meeting NCCN criteria.
5.3.3.1 Individual with an already known mutation. First the flowchart will check if the
individual has a known mutation of PTEN gene.
5.3.3.2 Personal history. Individual with a personal history of any of the following
diseases:


Bannayan-Riley-Ruvalcaba syndrome (BRRS)



Adult Lhermitte-Ducolos diseases



Autism spectrum disorder and macrocepahly



Two or more biopsy-proven trichilemmoas



Two or more major criteria



Three major criteria, without macrocepahly



One major and more than three minor criteria



More than four minor criteria
5.3.3.3 Family history. The program check the family history of close blood relatives

with any one or more major criteria or two or more minor criteria.
The test result will be stored before it enters into the next section.
5.3.4 Forecasting cancer in future offspring. Every child inherits two copy from their
parents; one from their mother and one from the father. BRCA1/BRCA2, Tp53 and PTEN genes
are not associated with x-linked inheritance. Therefore, the mutations can be inherited from
either parent. Offspring of the individual with any of these gene mutations can inherit the
mutation.
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As BRCA1, BRCA2, Tp53 and PTEN genes exhibit autosomal inheritance pattern, there
are four possible combinations for the children’s gene copy. As shown in figure 3, two of the
four, or 50 percent, can inherit the mutated genes (aA, aA). The other 50 percent do not inherit
the mutated genes (AA, AA). These four combinations are possible every time a pregnancy
occurs. The gender of the children (whether they are sons or daughters) does not matter. The
chance of getting normal child is 50/50 for each pregnancy. Consider a mother who carries
BRCA1 mutated gene, and her partner carries normal genes. In each pregnancy, the chances of
getting normal child is 50% and also chances of getting child with the abnormal gene is also
50%. We are using this information to predict the chances of hereditary breast cancer in the
offspring or the child to be born if the individual is analyzed at risk by this tool.
5.3.5 Output. In the final session, the output from different sections will be combined
and displayed along with the next generation’s risk. There will be different output based on the
different sections. The result contains mutated gene risk and breast cancer risk. The result also
displays the risk of passing mutated genes to next generation. In the output, it has been advised
that the result is not a substitution for professional genetic test. If the individual is at risk, we
recommend a discussion with an oncologist for better treatment. This program will have four
different outputs as shown in below. The outputs are based on different gene mutations analysis.
It includes BRCA1/BRCA2 analysis, Tp53 analysis, PTEN analysis and ‘not at risk’ situations.
The user can print the result and consult an oncologist for further assessments and treatments.
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Figure 18. Output – BRCA1/BRCA2 mutation.
The above figure represents one of the output. In this scenario, the person has met family history
criteria of HBOC syndrome analysis.

Figure 19. Output – PTEN mutation.
The above figure shows the analysis result from Cowden syndrome or PTEN gene mutation.
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Figure 20. Output – Tp53 mutation.
The figure- 15 is a screen image of the output of the program for a user who met the Tp53
mutation criteria.

Figure 21. Output – ‘not at risk’ case.
The above figure represents the output for a user who does not meet any criteria.
5.3.6 Features of the program.


Includes PTEN and Tp53 genes: This tool includes high-risk Tp53 and PTEN genes, and
none of the existing breast cancer tools available consider these high risk genes.



Consider ovarian, prostate, pancreatic cancer history.
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Included Ashkenazi Jewish history.



Available to the public: Many of the existing tools are proprietary and are not available to
the public. This tool is open source, and it will be available to the public.



User-friendly: This is a very easy-to-use software tool, and any person with basic
knowledge in computer operation can easily use it.



Easy to understand: It is easily understood by people who have little breast cancer
awareness.



Universal acceptance: This tool is designed based on NCCN guidelines, and it is not
restricted to a set of people based on their demography or ethnic group. The guidelines
have been developed in coordination with twenty-five global leading cancer centers.
Most of the existing tools have been developed based on the data collected from a
particular demography.



Includes third-degree relatives: Considers family history that includes first-, second-, and
third-degree relatives. Many tools available are not considering third-degree relatives and
family history.
Early detection and screening would help to prevent the cancer or to find the disease at an

early age. Taking drugs would prevent or delay cancer onset if you are at risk of hereditary breast
cancer syndrome. For example, medicines such as Tamoxifen and Raloxifene lower the breast
cancer risk in the general population (Moyer, 2013). Individuals at risk may choose to have
surgery to reduce their risk. The individual at risk is strongly recommended to have breast or
ovarian cancer screening, including mammograms, MRI exams, ultrasound, and breast exams,
performed by a physician.
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6

CHAPTER 6

Future Work and Conclusion
Predicting disease with computer modeling and mathematical analysis is becoming more
popular. Combining all known diseases and diagnosis would help medical practitioners to
determine and predict diseases in the current or next generations. As the years go by, family
health history stored in computers provides better assessments, accuracy, and standardization in
forecasting diseases. Computers could be trained to forecast and predict specific diseases. We
want to integrate this tool with other common inherited diseases such as cystic fibrosis, Down
syndrome, type 2 diabetes, inherited heart diseases, or other hereditary cancers, and that will help
both common people and medical professionals. We want to build this prototype as a
comprehensive computer application to predict most of the common inheritable and predictable
diseases. We like to add more hereditary cancers and improve the existing program with other
moderate risk genes such as PALB1, BRIP, and LKB1. We want to include the non-hereditary
risk factors that are related to lifestyle and diet. We also like to work on all known hereditary and
non-hereditary cancers and integrate them with this tool. In future, we are considering to
integrate this application with smartphone applications.
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